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Cancers develop as some cells acquire the ability, either by exogenous stimulation 
or by spontaneous mutation, to keep growing despite normal restraints. Up-regulating 
translation of oncogenes involved in cell proliferation and tumor development and down-
regulating translation of tumor-suppressors that normally suppress tumor development 
are two most common mechanisms by which cancers develop. Therefore, it is crucial to 
study how these proteins get either up-regulated or down-regulated at translational level. 
The eukaryotic translation initiation factor, which is composed of subunits such as 
eIF4A, eIF4G and eIF4E, is one of the key factors that contribute to efficient translation 
initiation. Interleukin 24 (IL-24), otherwise known as melanoma differentiation 
associated gene-7 (mda-7), is endogenously expressed by epidermal and immune cells 
and involved in wound repairing and fighting inflammation. Overexpression of IL-24 in 
cell lines is able to selectively induce apoptosis in various cancer cells while leaving 
normal cells intact (Sainz-Perez et al., 2008; Sauane et al., 2003; Persaud et al., 2016; 
Lebedeva et al., 2002; Jiang et al., 1996; Gopalan et al., 2007; Chada et al., 2005; 
Fonseca-Camarillo et al., 2014). Given this specific killing effect, IL-24 is being studied 
extensively and currently in phase II clinical trials as a promising cancer therapeutic. 
Sigma 1 receptor and mitochondrial dysfunction have been both found to be involved in 
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cancer development and treatment as well. The primary focus of this my thesis is that IL-
24 exerts its anticancer effects by restraining translation initiation of some key mRNAs 
for oncogenes by inhibiting subunits of eIF4F complex and inducing mitochondrial 
membrane disruption, and Sigma 1 receptor can rescue this killing effect by IL-24. 
Inhibition of inhibitory immune checkpoint such as PD-L1 is suggested to be part of the 
network by which IL-24 inhibits cancer cells. This work uncovers some new mechanisms 
of action that can be exploited to help develop anti-cancer therapeutics mainly composed 
of IL-24. Uncovering the details of IL-24-mediated apoptosis in various cancer cell lines 
will help develop personalized immune-therapies that can treat tumors in a more efficient 
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1.1 Cancer Development 
Cancers are caused by abnormalities that remove normal control on cell growth and 
proliferation and allow cells to over-develop despite the physiological signals that 
normally would regulate cell growth or induce apoptosis. During the past years, there has 
been increasing amount of research that shows interruption with some of the processed in 
normal cell functions significantly contributes to the formation and development of some 
kinds of cancers. One of these processes is translation initiation, which has a pivotal role 
in regulating cell growth, division, differentiation and apoptosis (Buzas et al., 2011; Wahl 
et al., 2009; Andoh et al., 2009; Wang et al., 2002; Chen et al., 2020; Tumia et al., 2020). 
Proteins are the direct executing molecules for most biological functions in eukaryotic 
cells and change of levels of these protein molecules can dramatically alter processes 
from cell proliferation, growth, apoptosis to the life course of the entire organism. This is 
supported by research results that show unregulated translation initiation has been linked 
to genesis and progression of many cancers and inhibition of translation initiation can 
restrain cell growth, proliferation and cancer development (Buzas et al., 2011; Wahl et al., 
2009; Andoh et al., 2009; Wang et al., 2002; Chen et al., 2020; Tumia et al., 2020; 
Srivastava et al., 2020). Therefore, it is of significant potential for curing diseases like 
cancers to study how the process of translation initiation is regulated, specifically in this 
work, how Interleukin 24 (IL-24), which is also known as melanoma differentiation 
associated gene-7 (mda-7) and a member of the IL-10 cytokine family, can modify 
translation initiation step in cancer cells to induce its cancer-only killing effect. 
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1.2 IL-24 
IL-24 is a secreted cytokine which uses IL-20R1/R2 or IL-22R2/IL-20R2 hetero-dimer 
receptors to promote signaling transduction and activator of transcription 1 (STAT1) and 
signaling transduction and activator of transcription 3 (STAT3) signaling pathways, 
causing expression of genes involved in cell growth and differentiation (Wang et al., 
2002; Sauane et al., 2003; Dumoutier et al., 2001). Hematopoietic cells such as peripheral 
blood mononuclear cells (PBMC), T cells, B cells, and monocytes can produce IL-24 in 
the presence of many external stimuli and exert various functions including wound repair 
and anti-inflammation (Wolk et al., 2002; Poindexter et al., 2005; Maarof et al., 2010; Jen 
et al., 2012). Studies have found that IL-24 can be highly induced in Th2 cells along with 
IL-10 and expression is dependent on IL-4/STAT6 signaling pathway. At physiological 
level, IL-24 has effects in wound healing, development of psoriasis and arthritis, host 
defense against organism invasion, and cardiovascular diseases as shown in the figure 1 
(Sauane et al, 2003; Dumoutier et al., 2001; Persaud et al., 2016).  
In addition to its physiological functions, the anti-cancer effects of IL-24 have been 
studied widely in the field. In the past few years, IL-24 has been extendedly studied as a 
very promising potential anti-cancer therapeutic due to that this pleiotropic cytokine has a 
very potent killing effect on various kinds of cancer cells including colon cancer, breast 
cancer, prostate cancer and liver cancer (Mao et al., 2020; Rastegari et al., 2020; Ghavimi 
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Figure 1. IL-24 physiological function. In response to certain external stimulation and internal changes, IL-
24 is at physiological level by monocytes, macrocytes and epithelial cells and binds to IL-20R1/R2 or IL-
22R2/IL-20R2 receptors to stimulate JAK1/STAT3 signaling pathways and is involved in fighting 
inflammation, wound repair and autoimmune diseases including inflammatory bowel disease, ulcerative 
colitis and Crohn’s disease.  
 
 
IL-24’s role in anti-cancer therapeutic was initially discovered by the experiment where 
exogenously induced overexpression of IL-24 inhibited tumor growth and only induced 
apoptosis in cancer cells and not healthy cells as shown in figure 2 (Lebedeva et al., 2002; 
Jiang et al., 1996; Gopalan et al., 2007). And after that experiment, there has been more 
and more research showing the same specific and selective anti-tumor effects by IL-24 in 
many other different types of cancers including melanoma, glioma and carcinoma of lung, 
breast and liver (Chada et al., 2005; Fonseca-Camarillo et al., 2014; Xue et al., 2006; 
Bhutia et al., 2011; Xie et al., 2008). Although overexpression of IL-24 has this anti-
cancer effect in so many types of cancers, IL-24 does not have any of this at its 
physiological level. And again, there has been no evidence showing that overexpression 
of IL-24 has any adverse effects on normal cells such as inhibition of growth or even 
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induced apoptosis (Dash et al., 2010; Menezes et al., 2014, 2018). 
There are different ways to overexpress IL-24 in cells, such as adenovirus infection, 
recombinant protein and cancer-specific oncolytic virus infection. While adenovirus 
infection of IL-24 causes cancer-selective killing effect, this method also exerts inhibitory 
effects on tumor vascularization, invasion and metastasis (Lin et al., 2014; Zheng et al., 
2007; Li et al., 2013; Li et al., 2011; Yacoub et al., 2008). In addition to working by itself 
to kill tumor cells, IL-24 has also been shown to work in orchestration with other anti-
tumor treatments including bevacizumab, which is a monoclonal antibody targeting 
vascular endothelial growth factor (VEGF); ZD55-TRAIL, which is an oncolytic virus 
that has a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene, 
gefitinib, which inhibits epidermal growth factor and other anti-cancer chemotherapeutic 
agents such as temozolomide and cisplatin, to which IL-24 can sensitize tumors (Yacoub 
et al., 2008; Bhutia et al., 2013; Saeki et al., 2002; Ramesh et al., 2003; Ramesh et al., 
2004; Shi et al., 2007; Sauane et al., 2008; Cai et al., 2012). 
Supported by the increasing amount of study, IL-24 is becoming a more and more 
favorable potential therapeutic for cancer treatment and management given its tumor-
selective killing, anti-vascularization and anti-metastatic characteristics that have been 
tested in both in vitro and in vivo studies. While we are getting so many positive results in 
both basic and clinical research, which has pushed IL-24 as a potential cancer therapeutic 
to the phase II clinical trials, the application of IL-24 in cancer treatment and 
management is still very much limited to only metastatic melanoma (McKenzie et al., 
2004). In the hope to break this barrier and expand IL-24 application, it is essential to 
increase and broaden the efficiency of IL-24 to allow it to benefit more patients with not 
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only melanoma but also other types of cancer such as leukemia, lymphoma, colon cancer 
and lung cancer and so on. In order to put this idea to test, patients with melanoma, 
lymphoma, hepatoma, breast cancer, non-small cell lung cancer, colorectal cancer, head 
and neck cancer, and cancers of the parotid gland, lip, kidney, bladder, adrenal gland, and 
penis, were enrolled in a clinical trial. The trial applied a non-replicative type 5 
adenovirus to induce IL-24 and applied repeated intra-tumoral injections in a dose-
escalating manner (Eager et al., 2008; Fisher et al., 2003, 2007; Lebedeva et al., 2007; 
Sarkar et al., 2007; Cunningham et al., 2005; Tong et al., 2005). In this phase I trial, 
researchers wanted to evaluate the safety, pharmacokinetics of vector DNA, and IL-24 
protein half-life both at the tumor site and distal from that. Ad.IL-24 was painted with 
isosulfan blue dye before being injected to track the distribution over time. Vector-
specific DNA and RNA were detected at the site of injection with highest intensity, 
which then faded in peripheral tissues, and minimum expression level was detected up to 
3-cm from the injection site. High levels of vector DNA and RNA were detected in 
tumors up to 24–48 hours after injection and the levels decreased by 3 logs of magnitude 
after 4 days but remained above baseline level after 30 days (Eager et al., 2008; 
Cunningham et al., 2005). This trial showed uplifting result that after repeated injections 
of Ad.IL-24 directly into the tumor and tissues around the tumor were safe and well 
tolerated by the patients. Furthermore, a delightful 44% patient response rate was 
prominent in injection sites (Cunningham et al., 2005; Tong et al., 2005). Apparently, in 
order to achieve the ultimate goal, which is to expand application of IL-24 to various 
types of cancer, we need to first try to unveil the mechanisms behind IL-24’s anti-cancer 
effects at different levels, and my research focuses on molecular mechanisms at 




Figure 2. IL-24 overexpression kills various types of cancer cells and leaves normal cells intact. 
Overexpression of IL-24 by either recombinant protein or adenovirus infection has been tested and shown 
killing effects in cancers including prostate cancer, melanoma, lung cancer and colon cancer. Whereas the 
same overexpression of IL-24 by either recombinant protein or adenovirus has been shown to have no 
effect on normal and healthy cells including prostate epithelial cells, healthy melanocytes, healthy breast 
epithelial cells. These tests suggest that IL-24 has a cancer-specific killing effects and not on healthy cell 
counterparts. In this work, we tried to define the mechanisms for this cancer-specific killing effect. 
 
 
1.3 Translation Initiation and eIF4F complex 
While cancer cells are heavily dependent on protein synthesis to proliferate, the most 
pivotal step during translation process is the initiation step, which involves two major 
complexes: ternary complex and eIF4F complex. The eukaryotic Initiation factor 2 (eIF2) 
and the initiating methionyl-tRNA (Met-tRNAi) form the ternary complex. The ternary 
complex recruits the 40S ribosomal subunit to form the 43S pre-initiation complex. The 
43S pre-initiation complex then binds to the mRNA cap with the participation of other 
translation initiation factors, such as the eIF4F complex. The pre-initiation complex scans 
the 5′ untranslated region (5′ UTR) of the mRNA. While, according to some research 
results, these two complexes are coordinated by mTOR complex and casein kinase 
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(Kawabe et al, 2002), this work primarily focuses on the eIF4F complex and its 
modification by IL-24. 
Eukaryotic initiation factors (eIFs), shown in figure 3, are protein subunits that play 
important roles in the translation initiation step including stabilizing the mRNA that is 
about to be translated as well as recruiting ribosomal subunits to the mRNA followed by 
scanning and translation of the mRNA into protein molecules. Several subunits of eIF4 
complex will first bind with small 40S subunit of ribosome and the tRNA for consensus 
start codon in eukaryotic cells: Met-tRNA, forming a complex called 43S pre-initiation 
complex (43S PIC). The 43S PIC is then recruited by eIF4 complex, which is composed 
of eIF4A, eIF4E and eIF4G, to the 5’ CAP and scans along the mRNA until it encounters 
the start codon AUG on the mRNA, which will attract the large ribosomal subunit 60S to 
the translation site to form the entire 80S ribosome and the translation can continue until 
the stop codon is reached and translation machinery is released from the mRNA. During 
the assembly of eIF4F complex, eIF4E can recognize the target mRNA and binds to its 
methyl groups, followed by recruitment of eIF4G subunit to bind to eIF4E, where eIF4G 
acts as a scaffold to associate with PABP which in turn attaches to poly-A tail to stabilize 
the target mRNA in a loop structure. Then eIF4A will be attracted by eIF4G to form the 
final eIF4F complex prior to initiation of translation (Valentina et al., 2016). 
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Figure 3. Structure of eIF4F complex. eIF4F complex has 3 subunits: eIF4A, eIF4G and eIF4E. This 
complex is assembled at the 5’UTR of the targeted mRNA prior to initiating translation process. eIF4E can 
recognize and associate with methyl group at the beginning of the target mRNA, followed by recruiting and 
binding eIF4G. eIF4G can associate with poly-A tail binding protein which associates with Poly-A tail of 
the target mRNA to stabilize it in a loop structure. Finally, eIF4A is recruited to eIF4G at the frontmost 
area of the complex, completing the eIF4F complex. 40 S ribosomal subunit associated with Met-tRNA is 
called 43S complex, which is also required for translation initiation to start. 
 
 
eIF4F could be the key discriminatory factor that is responsible for different translation 
rates between different mRNAs. In support to this notion, different mRNAs have shown 
varying affinities to eIF4F—a feature that was presented as the levels of mRNA 5’-UTR 
secondary structure (Sarkar et al., 1984; Edery et al., 1984; Howard et al., 2020). In 
contrast to eIF4F discriminating between different mRNAs based on secondary structures, 
translation initiation rates on plain, unstructured mRNAs is not as heavily dependent on 
eIF4F, the cap sequences, or ATP (Pestova et al., 2002; Kardos et al., 2020). Also, a 
dominant-negative mutation of eIF4A, which is able to inhibit eIF4F activity, shows less 
severe inhibition on translation of mRNAs with a less structured 5’-UTR when compared 
with transcripts that contain more complex structures (Svitkin et al., 2001; Tupperwar et 
al, 2020).  
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The eIF4F complex is made of eIF4A1, eIF4A2, eIF4B, eIF4E, eIF4G and eIF4H 
subunits. Each of these subunits has their own functions and they work together 
cooperatively to make translation happen.  For example, eIF4B is essential for ribosomal 
subunit 48S initiation complex formation on mRNAs possessing, with even slightest level 
of 5’-UTR complexity (Dmitriev et al., 2003) and its depletion results in significantly 
decreased cell proliferation, survival and promoted reactivity to camptothecin-induced 
cell death (Shahbazian et al., 2010). These results suggest eIF4B’s role in controlling the 
translation of mRNAs critical for cell proliferation and survival. Also, there are research 
groups that have shown interaction between eIF4E and the mRNA 5’ Cap is crucial for 
the translation initiation and this interaction is highly dependent on the binding of RNA 
to eIF4GI (Chu et al., 2015; Robert et al., 2020; Diaz et al., 2020). After initial 
transformation, growth and proliferation, sometimes tumor cells can acquire the ability to 
leave the original site, go through the basement membrane and travel to distant sites in 
the organism to form a new colony and new tumor, which is called metastasis. The 
complex and specific mechanisms under this phenomenon is still under extensive study, 
but one of the subunits of eIF4F--eIF4E stood out as a critical mediator in this process as 
initial antisense RNA studies in ras-transformed fibroblast cells showed that mild 
decrease of eIF4E can lead up to 90% decrease of metastasis in mice lung cancer. 
Following study where these modified cancer cells were injected into mice renal capsule 
and failed to observe any infiltration of parenchymal tissue. Moreover, when metastasis 
does happen with these cells, they were found to have restored level of eIF4E (Graff et al., 
1995). These early research results suggest a key role of eIF4E for the process of tumor 
metastasis, which is considered the ultimate and final irreversible stage for most cancer 
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patients. It would be safe to say that it is of huge potential benefit to study more about the 
role and contribution of eIF4E in cancer development and metastasis as a future 
therapeutic. 
In this thesis, the key subunit of eIF4 complex, which needs to be tightly and closely 
regulated in cancer cells and influences the expression of mRNAs responsible for 
oncogenic signaling, is eukaryotic initiation factor 4A (eIF4A). Mammals possess two 
highly related eIF4A paralogs: eIF4A1 (DDX2A) and eIF4A2 (DDX2B), which in 
humans are 90% identical at the amino acid level. eIF4A1 is more abundant and better 
studied than eIF4A2. In vitro, the two isoforms exhibit similar biochemical activities. 
However in vitro, their roles may not be equivalent. Notable differences include the 
following, eIF4A1 is predominantly synthesized during active cell growth, whereas 
eIF4A2 is produced during growth arrest; Suppression of eIF4A1 leads to increased 
eIF4A2 levels, but this change is insufficient to compensate for the ensuing cell death 
associated with eIF4A1 loss; eIF4A1 is essential for cell survival, but eIF4A2 is not (Lu 
et al., 2014; Raza et al., 2015; Nebigil et al., 2020; Shen et al., 2020). 
 eIF4A is a helicase that binds to the 7-methylguaniylate cap (m7G) at the 5’ end of the 
messenger RNA and unwind mRNAs for translation to occur and continue with the help 
from eIF4G and eIF4B (Alexandra et al., 2013; Ali et al., 2011; Alexandra et al., 2014). 
Also, there are results that suggest increased activity of the translation initiation factor 
eIF4A is linked with more efficient translation of mRNAs encoding for the pro-survival 
X-linked inhibitor of the apoptosis (XIAP) and B-cell lymphoma and STAT1 promotes 
KRAS colon tumor growth and susceptibility to pharmacological inhibition of translation 
initiation factor eIF4A (Wang et al., 2015; Shuo et al., 2016). Furthermore, inhibition of 
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eIF4A1 subunit using a small molecule member of the flavegline family is followed by 
killing effect of NRAS-mutant cancer cell lines (Bordeleau et al., 2008; Cencic et al., 
2009). There are also many studies showing that targeting eIF4A can significantly impair 
the translation initiation step for some crucial proto-oncogenes and appears to be a very 
promising therapeutic choice for many kinds of tumors including breast cancer, lung 
cancer and melanoma (Gingras et al., 1999; Shen et al., 2019; Webb et al., 2020). In 
addition, some groups have shown that Knockdown experiments of eIF4A reduced 
proliferation and induced cell death in cancer cell lines (Galicia-Vazquez et al., 2012; 
Robert et al., 2014). Furthermore, in murine models, overexpression of eIF4A accelerated 
leukemia and sarcoma development as well as drug resistance (Svitkin et al., 2001; 
Chang et al., 2020). Several eIF4A inhibitors are currently under investigation and are 
thought to exert their effects by translational inhibition of key oncogenes such as c-MYC 
(Svitkin et al., 2001; Galicia-Vazquez et al., 2012; Robert et al., 2014). 
With so much known about eIF4F complex and its subunits, the idea of fighting cancer 
by inhibiting eIF4F complex has been tested widely. For example, depletion of 
asparagine has shown inhibition on translation elongation and has been used clinically to 
treat acute lymphoblastic leukemia and acute myeloid leukemia in children (Hill et al., 
1967). Moreover, homoharringtonine as an inhibitor of translation elongation has been 
approved by FDA to treat chronic myeloid leukemia (O'Brien et al., 1995; Gilles et al., 
2020). There are 3 natural products found to specifically inhibit eIF4A: pateamine A (Pat 
A), hippuristanol, and silvestrol (Bordeleau et al., 2005, 2006, 2008). Out of these three 
products, silvestrol has been shown to have the most potential to become an anti-cancer 
therapeutic given its strongest inhibiting effects on cancer cells and least side effects on 
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other normal cells such as liver cells and immune cells in mice studies (Cencic et al., 
2009). Biologic availability of silvestrol after intraperitoneal injection is 100% and it has 
a 60% of parental remaining after 6 hours (Saradhi et al., 2011). The inhibition by 
silvestrol on cancer cells is most likely due to its inhibition on eIF4A since silvestrol-
resistant eIF4A mutation can allow cancer cells to survive and proliferate well in 
exposure to silvestrol treatment (Sadlish et al, 2013). In accordance with current 
speculations, the translation of mRNAs with highly structured 5’-UTR is more liable to 
silvestrol treatment compared to those that have simple 5’-UTR (Cencic et al., 2009).  
Intriguingly, cancer cells appear to be highly dependent on RNA helicases to keep up not 
just general increase in protein production, but also for translation of many oncogenic 
mRNAs to promote proliferation and survival (Truitt et al., 2016). The oncogenes that are 
more reliant on helicase eIF4A include but not limited to MYC, NOTCH1, MYB, CDK6, 
MDM2, CCND3, BCL2, ETS1, ADAM10, LEF1, BCL10, MALT1, ARF6, CCND1, 
ROCK1 (Wolfe et al., 2014; Cencic et al., 2009). 
As important as eIF4F complex and ternary complex are, they are mostly involved in 
mRNA cap-dependent translation where the 5’ cap and 5’UTR sequence play a crucial 
role in translation initiation. Whereas in some other mRNAs, 5’ cap and 5’UTR are not as 
crucial as they rely more on cap-independent translation where translation of the target 
mRNAs does not require the cap sequence and 5’UTR, instead these mRNAs either have 
Internal Ribosomal Entry Site (IRES) or TISU sequence that is flanking the start codon in 
mRNAs with short 5’UTR for efficient translation to happen. It is the ochestration 
between cap-dependent and cap-independent translation that maintains the effactive 
translation when cells are under different stress such oxidative stress and heat shock 





1.4 Sigma 1 Receptor 
Historically Sigma1 Receptor (S1R) was considered a traditional receptor. Most 
publications regarding S1R describe it in the context of neuropharmacology, in which 
S1R modulates ion channels and regulate their respective currents. Also, S1R has long 
been known to be involved in addictive effects (Cobos et al., 2008; Maurice et al., 2009). 
Over the years, there has been emerging evidence suggesting that S1R is a nontraditional 
receptor and instead a trans-membrane protein at ER membrane that can translocate 
between cell membranes such as cytoplasmic membrane, ER membrane and 
mitochondrial membrane as shown in figure 4 (Yanagiya et al., 2009; Ebru et al., 2002; 
Teruo et al., 2003). Scientists have later found that S1R is a protein chaperone, through 
whose regulation by specific ligands can have either cytoprotective or cytotoxic effects 
(Su et al., 2016) and it functions as a novel and pharmacologically regulated integral 
membrane chaperone (Hayashi et al., 2007) and scaffolding protein that regulates ion 
channels and relevant ligands biosynthesis in cancers (Crottès et al., 2011).  
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Figure 4. Sigma 1 receptor (S1R). Sigma 1 receptor is an integral membrane protein of 26 kDa that is 
unrelated to any traditional transmembrane receptor. S1R is predominantly expressed in ER membrane and 
functions as a protein chaperone as well as regulating calcium transport between ER and mitochondria. 
S1R is over expressed in several pathological conditions, including neurodegenerative diseases such as 
Alzheimer disease, Parkinson disease and cancers including esophageal squamous cell carcinoma, prostate 
cancer, breast cancer.    
 
 
S1R is over-expressed in many kinds of cancer cells, including breast and prostate cancer 
cell lines (Vilner et al., 1995; Ayadar et al., 2004; Spruce et al., 2004). While in a clinical 
study of esophageal squamous cell carcinoma patients, increased S1R expression is 
associated with poor prognosis, faster progression, bigger tumor size, higher TMN 
staging at the diagnosis and short survival time (Xu et al., 2014).  It has also been 
observed that this S1R overexpression in the plasma membrane of various human cancer 
cell types contributes to the proliferation, invasion and metastasis of these cancers (Van  
et al., 2015). Interestingly, S1R antagonists and S1R knockdown via RNAi, have been 
shown to decrease cell mass and deactivate key regulators of translation such as 
ribosomal protein S6 kinase beta-1 (p70S6K), S6 and 4EBP1 (Kim et al., 2012). 
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Moreover, it has been observed that various types of cancer cells that naturally produce 
S1R, when treated with S1R putative antagonists become smaller than control cells. 
These antagonists of S1R caused cell shrinkage through inhibition of Cap-dependent 
translation initiation (Felix et al., 2012). Under certain stressors for a particular period of 
time, cells would have increased expression and altered distribution of S1R from MAM 
to the periphery of ER system, which then regulates the mobilization of Ca2+ from 
mitochondria to ER to fight ER stress and prevent cell death (Teruo et al., 2007). More 
recently, Maher and his team discovered that knockdown and inhibition of S1R is 
associated with decreased PD-L1 surface expression level, which in turn increases 
immune response by T cells on cancer cells in order to suppress tumor development and 
progression (Maher et al., 2018). On the other hand, modulation by S1R agonists and 
antagonists have also been shown to play a role in cancer. Specifically, branched-chain 
ammonium salts, including bis (2-ethylhexyl) ammonium and triisopentylammonium 
which act as S1R antagonists, are shown to inhibit tumor growth and development in vivo 
(Brimson et al., 2020). In addition to its role in treatment for cancer, S1R has also 
displayed some value in cancer diagnosis due to its high expression level across various 
types of cancer. For example, Everaert et al. found that a radiolabeled benzamide S1R 
ligand 123I-IDAB (123I-N-(2-diethylaminoethyl)-4-iodobenzamide) can be used to detect 
melanoma with a high accuracy (Everaert et al., 1997). Following this initial study, 
another S1R derivative (123) I - N-(2-diethylaminoethyl)-2-iodobenzamide ((123) I-
BZA2) was found to be very sensitive for detecting melanoma metastasis (Florent et al., 
2014). In another study in 2017 Haloperidol, a S1R antagonist, was found to effectively 
induce cell death in liver cancer (Bai et al., 2017). 
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Our group has previously demonstrated that S1R is the common upstream initial signal 
transduction molecule involved in IL-24-induced cancer-specific apoptosis (Do et al., 
2013). We have also discovered that IL-24’s action in cancer cells is mediated by an 
antagonistic effect of IL-24 on S1R. S1R antagonist-mediated cell death is inhibited by 
the prototypic S1R agonist SKF10047 or by overexpression of S1R (Persaud et al., 2016; 
Do et al., 2013). Therefore, it is of notable significance, in this work, to elucidate more 
about the role of S1R in the effects of IL-24. 
 
 
1.5 Mitochondria in Cancer 
Mitochondria are the most important organelle responsible for cell metabolism and 
energy supply and their changes in metabolism in cancer has been studied widely in the 
field. Cancer cells have higher metabolic needs and antioxidant defenses compared with 
healthy cells. They rely heavily on aerobic glycolysis to meet their energy needs, which is 
mainly provided by mitochondria. Furthermore, aerobic glycolysis leads to the 
production of large amounts of lactate and pyruvate, causing increased acidity in the 
cytoplasm in cancer cells which causes mitochondria to be hyperpolarized compared with 
normal cells. This hyperpolarization can also be the result of increased intracellular Ca2+ 
levels and upregulation of anti-apoptotic Bcl2 protein, leading to increased apoptosis 
evasion. So by either inhibiting mitochondrial function or depolarizing mitochondrial 
membrane, which can release Cytochrome c to initiate caspase cascade, can largely 
induce cancer cell apoptosis. Moreover, the most prominent metabolic modifications in 
cancer cells is the upregulated glycolysis even with abundant oxygen available, which is 
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named Warburg effect. This aerobic glycolysis process was initially seen as a sign of 
impairment of oxidative phosphorylation in cancer cells. Later on with more research 
results, increasing amount of evidence suggests that cancer cells are dependent on 
mitochondria for the bioenergetic machinery and synthesis of protein, lipid and 
carbohydrates (Weinberg et al., 2015), particularly when undergoing external stress, such 
as chemotherapy (Vellinga et al., 2015), radiation therapy (Qin et al., 2015) and during 
metastasis (Lebleu et al., 2014). 
As expected, mitochondrial respiration has been deemed as a promising target for cancer 
therapeutics (Weinberg et al., 2015). Considering the importance of mitochondrial 
translation products in oxidative phosphorylation, targeting mitochondrial translation 
would be a reasonable method to fight cancers and has been proved to be a therapeutic 
approach to treat acute myeloid leukemia (Skrtic et al., 2011). While mitochondrial 
metabolism and function may change and adapt to cancer cells’ needs, there are some 
situations where mitochondria can be damaged and the cells will try to sacrifice them in 
order to preserve the entire cell through distinct pathways and mechanisms such as 
mitophagy (Ashrafi et al, 2013). These mechanisms can save cells from certain levels of 
mitochondrial damage or stress, but when the damage is too severe or lasts for too long 
that the cells do not have the chance or capability to handle, or when the salvage 
mechanisms are impaired, then those defective and damaged mitochondrial will 
accumulate and ultimately lead to cell death and tissue injuries. Besides, IL-24 has 
previously been shown to disrupt mitochondrial function and induce ROS production, 
shifting cancer cells from pro-survival mode to pro-apoptotic mode contributing to cell 
death in prostate cancer cell line as shown in figure 5 (Lebedeva et al., 2003). 
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Figure 5. IL-24 overexpression leads to mitochondrial membrane disruption and eventually cancer cell 
death. It has been established that inhibition of eIF4A triggers mitochondrial-mediated apoptosis by 
inhibiting translation of mRNAs with long 5’UTRs encoding proteins that maintain mitochondrial 
structural integrity (e.g., Bcl-2, Mcl1, and BIRC5). Therefore, in this work we investigated the effects of 
IL-24 on mitochondrial function and its role in IL-24 killing effects. 
 
 
1.6 Immune checkpoint blockade in cancer treatment 
 
Using patients’ own immune system to combat cancer has already existed since 1891, 
when William B. Coley introduced live streptococcal antigens into a patient with 
inoperable tumor to stimulate the patient’s immune system, which then cured the patient. 
This invention was the first recorded case of what we now call cancer immunotherapy 
(Coley et al., 1893). However, without enough understanding of our immune system and 
with fast development of chemotherapies and radiotherapy, immunotherapy has been left 
in the shadow in cancer management until a few years ago. 
With increased amount of evidence, we found out that immune cells (T cell, B cell and 
NK cells) play a crucial part in fighting malignant cells (Chen et al, 2013). Disruption of 
the patients’ immune system results in cancer cells escaping from immunosurveillance. 
While many mechanisms have been proposed for cancer cell evasion from immune 
system, blocking and stimulating some key protein mediators called “immune checkpoint” 
by cancer cells has stood out over the past few years, due to the enlightening patients’ 
responses to therapeutic agents targeting some of these “immune checkpoints” as shown 
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in figure 6. 
Back in 2013, the “Breakthrough Prize of the Year in Life Sciences” was given to Jim 
Allison, who has since led the field in searching for more understanding about the 
interaction between human immune system and malignant cells. Specifically, immune 
checkpoints are a group of protein molecules that regulate immune system to achieve a 
fine balance between eliminating foreign bodies while not harming self and these 
checkpoints can be divided into stimulatory and inhibitory checkpoints. Cytotoxic T 
lymphocyte-associated molecule-4 (CTLA-4) and programmed cell death receptor-1 (PD-
1) were the first characterized immune checkpoints, which upon binding to their 
respective receptors can inhibit immune system response (Pardoll et al., 2012). These 
inhibitory checkpoints have been shown to be used by cancer cells to avoid 
immunosurveillance. Hence, blocking CTLA-4 and/or PD-1 signaling pathway with 
specific antibodies or drugs could provide patients significant suppression on tumor 
growth and long-term survival and this approach is termed immune checkpoint blockade 
therapy (ICB). This approach has been tested in multiple types of cancer including lung 
cancer, melanoma, liver cancer and sarcoma. In one of the recent studies, Li and 
colleagues discovered that inhibition of PD-L1 with MDM2 ligand Nutlin-3 provides 
suppression on growth of sarcoma and melanoma (Li et al., 2020).  
In 2011 the FDA passed the very first ICB drug ipilimumab, which is an anti-human 
CTLA-4 monoclonal antibody, to treat patients bearing advanced melanoma. That move 
marked a whole new chapter in cancer treatment. Since then, anti-PD-1 drugs 
(pembrolizumab and nivolumab) and anti-PD-L1 drugs (atezolizumab, avelumab, and 
durvalumab) have been passed by FDA for treating patients with various types of cancer 
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such as non-small cell lung carcinoma, kidney cancer, leading to the awarding of the 
2018 Nobel Prize in medicine to Jim Allison and Tasaku Honjo. Given all this promising 
initial results and studies, ICBs have been widely tested in patients with various types of 
cancer including breast cancer, lung cancer and melanoma with favorable results and 
cancer remission (Egen et al., 2019; Melosky et al., 2020). 
Despite the impressive clinical response to ICBs, their application has been largely 
limited to a small group of cancer patients (Larkin et al., 2015). This limitation is largely 
due to primary and acquired resistance that eventually leads to tumor recurrence and 
progression. For example, a recent clinical study involving 45 melanoma patients treated 
with anti-PD-1 therapy showed only 30% had response to the treatment and tumor 
regression while the other patients did not have significant reaction (Hamid et al, 2019). 
In order to expand the use and efficacy of ICBs therapies, scientists have dedicated effort 
in understanding the mechanism for this resistance. So far, scientists have found that 
factors including T cell function, PD-L1 expression and tumor microenvironment can 
affect the response rate and efficacy of ICBs. Specifically, when T cell recognition, 
activation, differentiation, infiltration, depletion or chemotaxis is disrupted or inhibited, T 
cell function in fighting cancer cells will be largely suppressed (Ren et al., 2020). 
Furthermore, ICBs can induce life-threatening immune-related adverse events (irAEs) in 
certain patients and it is quite expensive to use these drugs for long time. Thus, more 
research needs to be done to understand the mechanisms of these drugs as well as 
identifying relevant biomarkers for clinical response to ICBs and designing combination 
therapies between different ICBs and ICBs with other traditional therapies to achieve 
better efficacy, efficiency and cost-effect ratio. In the meantime, other pathways have 
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been identified and drugs have been developed in regulating immune system activities, 
such as blockage of LAG-3, TIM-3 have been under intensive investigation (He et al., 
2016; Woo et al., 2012; Goldberg et al., 2011). Furthermore, agonists of stimulatory 
checkpoints such as ICOS, CD40, as well as molecules that target tumor 
microenvironment (TME) components like IDO or TLR have also gained a lot of 
attention (Bilir et al., 2017; Siu et al., 2017). 
In this thesis, our group has gained some evidence that suggests IL-24 might play a role 
in the immune checkpoint regulation as an upstream coordinator to inhibit PD-L1’s 
inhibition on T cell activation and function both in vitro and in vivo. With our results, we 
have a better understanding about how IL-24 exerts its cancer-selective killing effects as 
well as expanding the knowledge about the immune checkpoint blockade application in 
more cancer types and hopefully will help clinicians with immunotherapies that last 




Figure 6. PD-L1 expression levels and activity are closely related to the immune response to cancer cells 
and tumor growth. With high expression levels and increased activity of PD-L1, immune system including 
T cells activity and normal response to cancer cells will be inhibited and tumor growth will be uninhibited. 
Whereas when PD-L1 expression level and activity are inhibited, T cell and other immune cells can 
generate robust response to cancer cells and inhibit cancer cell survival and tumor growth. In this work, we 
tried to define if IL-24 can inhibit PD-L1 expression level as a mechanism for its cancer killing effect. 
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1.7 Research Purpose 
One of the goals of this work largely focuses on uncovering how IL-24 treatment in 
cancer cell lines can display its cancer-selective killing effects through different signaling 
transduction pathways with different intermediators. This goal has been broken down to 
specific parts in order to support the phenomenon that IL-24 selectively causes apoptosis 
in cancer cells due to it halts the translation initiation step and depletes intracellular 
calcium ion store. To further elucidate how IL-24 impairs translation initiation and 
calcium mobilization, Si1R, as well as eIF4A1 have been extensively studied in this 
project to map their respective roles in IL-24 anti-cancer effects. 
Another goal of this work is to expand the application spectrum of IL-24 as an anti-
cancer therapeutic from only melanoma to other types of cancers and also increase the 
efficiency of this treatment in melanoma patients. The reason for this goal is due to the 
plaguing hurdle amongst cancer treatments that no drug has been developed to work for 
many types of cancer, most the treatment can only fight one specific type of cancer and 
their efficacy usually drops down significantly after some time into treatment regimen. 
Hence, understanding the molecular mechanism by which IL-24 exerts its cancer-killing 
effects will potentially help resolve this big hurdle preventing better treatments for cancer 
patients. 
Also, in this work we try to define the relationship between IL-24 and immune 
checkpoints to broaden its usage to more types of cancer with better and longer response 
as a thriving immune-therapeutic. To this date, there has been an increasing body of 
research showing that by either inhibiting inhibitory checkpoints or simulating 
stimulatory checkpoints alone or with other treatment can give a subset of cancer patient 
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drastic improvement, but this improvement is either too short or limited to certain 
patients (Marin-Acevedo et al., 2018). In order to combat these two major hurdles, we 
need more research to uncover the mechanisms behind the response to this kind of 
treatment. 
The new insights gained in this work will benefit both scientists and physicians in 
transiting basic research to clinical studies, which will help develop better treatments for 
patients with more specific, more personalized and, most importantly, more widely 
applicable methods. This thesis presents some new findings about IL-24’s cancer-
selective inhibitory effects mechanisms and targets that can help take future cancer 







































- 26 - 
 
2.1 Gene Cloning 
E.Coli are transformed with respective gene construct using SIG10 5 alpha Chemically 
Competent Cells (Purchased from SIGMA) following the manufacturer’s instructions. 
Transformed bacteria are grown in LB liquid media overnight and inoculated on agar 
plates, the next day individual colonies were picked and put into LB media to grow 
overnight, 24 hours later, bacteria are collected following instruction by Midi-prep kit 
(purchased from Qiagen, Cat log #12143). 
 
2.2 Cell culture and Conditions 
All human cell lines (cervical cancer: HeLa; breast cancer: MCF-7, MDA-MB-231, 
prostate cancer: PC-3, DU-145) were purchased from American Type Culture Collection 
(ATCC), maintained per ATCC protocols and utilized within six months of thawing each 
vial. Cell lines were grown in a humidified atmosphere at 37°C with 5% CO2 and culture 
media was replaced every other day. 
 
2.3 Virus Infection 
After attachment within 24 h, cells were infected with the IL-24 expressing replication 
defective adenovirus (Ad.IL-24) or the control, a corresponding empty adenovirus vector 
lacking exogenous gene (Ad.vector). The adenoviruses were custom made by Vector 
Biolabs, Inc. (Philadelphia, PA). 
 
2.4 Transfection of Oligonucleotides 
Cells were seeded in 10-cm petri dishes. After reaching 60%-70% confluence, media was 
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replaced with Opti-MEM (Thermo Fisher Scientific Inc.; Wilmington, DE, USA) and 
cells were transfected with corresponding gene construct, using Lipofectamine 2000 
(Thermo Fisher Scientific Inc.; Wilmington, DE, USA) according to the manufacturer’s 
instructions. Transfected cells were then incubated at 37°C for a total duration of 24 h 
before cells were sub-cultured into 6-well plates and then treated with either empty virus 
or Ad. IL-24 virus, followed by dual luciferase assay reading. 
 
2.5 Western Blot Analysis 
Cellular protein was extracted using Pierce IP Lysis Buffer (Thermo Scientific, Rockford, 
IL) and a mixture of Halt Protease Inhibitor Cocktail 100X (Thermo Scientific, Rockford, 
IL) and Phosphatase Inhibitor Cocktail 100X (Cell Signaling Technology, Danvers, 
Massachusetts). Fifty-sixty micrograms of protein were applied to a 10% SDS/PAGE and 
transferred to nitrocellulose membranes. Membranes were incubated with Odyssey 
blocking buffer (LI-COR Biosciences, Lincoln, Nebraska) prior to incubation with 
polyclonal or monoclonal antibodies to eIF4A, eIF4E, eIF4G, Cdc25C, XIAP, Mcl1, 
BIRCA5, alpha-tubulin, Caspase-3 and β-actin overnight at 4°C. All primary antibodies 
were purchased from Cell Signaling Technology (Danvers, Massachusetts). Goat anti-
rabbit IgG (H+L) 800 CW, goat anti-rabbit (680 RD) and/or goat anti-mouse (H+L) 
secondary antibodies were applied for 1 h at room temperature (1:25000, LI-COR) prior 
to washing with 1X Tris Buffered Saline Tween-20 (TBS-T). Visualization was carried 
out with the LI-COR Odyssey CLx imaging system and software. 
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2.6 RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction (qRT-
PCR) 
Total RNA was isolated by using the RNAeasy kit (Qiagen). Reverse transcription (RT) 
was performed on 5 ng of total RNA with an oligo(dT) primer. cDNA corresponding to 5 
ng of total RNA was amplified for 35 cycles by PCR with specific primers as previously 
described (Sauane M et al, 2010). Sequence-validated QuantiTec probes for eIF4A, 
eIF4B, eIF4G, Cdc25C, c-myc, ornithine decarboxylase, Bcl-2, Mcl1, Birca5, X-linked 
inhibitor of apoptosis, Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and alpha-
actin purchased from Qiagen Bio-technology were used for these mRNAs. 
 
2.7 Dual Luciferase Assay 
Luciferase reporters (kindly provided by Dr. Ivan Topisirovic) and luciferase assays were 
described previously (Gandin V. et al, 2016). HeLa cells were seeded in a 10 cm Petri 
dish and next day transfected using 30 uL of Lipofectamine 2000 (Invitrogen, Carlsbad, 
CA, USA), 600 ng of control Renilla (kindly provided by Drs. Yuri Svitkin and Nahum 
Sonenberg) and 1.2 ug of the firefly luciferase constructs. The next day, cells were 
seeded in triplicate in a 12-well plate and translation of the indicated reporters was 
monitored 48 h post-transfection using Dual Luciferase Assay System (Promega, 
Madison, WI, USA) according to the manufacturer’s instructions. 
 
2.8 Mitochondrial Membrane Potential Assay 
Mitochondrial membrane potential was monitored in intact cells by confocal microscopy 
using tetramethylrhodamine ethyl ester (TMRE), which can only accumulate in 
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mitochondria when they are active. HeLa cells were seeded on 25 mm cover slips at a 
density of 600,000 cells/well, grown for 48 h, and then incubated with JC1 (10 _g/mL) 
for 2 h. The cover slip was washed twice and mounted in a cell chamber (ALA Scientific 
Instruments, Westbury, NY, USA). 
 
2.9 Annexin V Binding Assay 
Cells were trypsinized, washed once with complete medium and PBS, resuspended in 0.5 
mL of binding buffer containing 2.5 mmol/L CaCl2, and stained with allophycocyanin-
labeled Annexin V (Becton Dickinson Biosciences, Palo Alto, CA, USA) and propidium 
iodide (PI) for 15 min at room temperature. Flow cytometry assays were performed as 
previously described (Persaud L et al, 2017). 
 
2.10 Mice and mice colon cancer cells 
C57BL/6J mice are purchased from The Jackson Laboratory. Colon cancer cells are 
purchased from Kerafast.  Two 8-week old C57BL/6J female mice were put in one cage 
and let accommodate for 2 weeks. On day 0, 1 x1010 MC38 cells were mixed in 100 ul 
PBS and injected into each mouse subcutaneously at their right flank. Mice tumors were 
observed and measured every day. On day 16, tumors become palpable in each mouse. 
185 ul of PBS was injected into tumor 1 and 185 ul of Ad.IL-24 was injected into tumor 
2. On day 22, mice were sacrificed and tumors were harvested and measured 
 
2.11 Statistical Analysis 
Data was compiled from at least three independent experiments. All results are presented 
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as mean ± standard error of the mean (SEM). Unless otherwise indicated, analysis of 
statistical significance of differences between groups was determined using two-tailed 
Student’s t-test. Only values with P < 0.05 were considered statistically significant. 
Statistical differences in the relative mRNA expression profiles were determined with 
one-way analysis of variance (ANOVA) using the SPSS Statistics software (http://www-
01.ibm.com/software/analytics/spss/) on normalized data. Only values with P < 0.05 were 






























Chapter 3: Eukaryotic translation initiation factor 4A down-regulation mediates 
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3.1 Introduction 
Cancer cells lose the physiologic restraints on the cellular translational machinery, 
leading to increase in both global protein synthesis and translation of specific mRNAs 
that promote tumor cell survival (Hinnebusch et al., 2016). Translation initiation plays a 
critical role in the physiological regulation of cell proliferation, differentiation and 
apoptosis. Unrestricted translation initiation not only critically contributes to the 
maintenance and progression of cancers but also causes malignant transformation 
(Ruggero et al., 2013; Silvera et al., 2010). Two major rate-limiting steps in translation 
initiation regulation are the assembly of ternary complex (TC) and eIF4F complexes 
(Hinnebusch et al., 2014). Targeting translational control, especially the eIF4F translation 
complex is currently at the forefront of the development a promising therapeutic strategy 
(Duncan et al., 1983; Galicia-Vazquez et al., 2012). 
Dysregulated activity of helicase eIF4A drives transformation to and maintenance of 
cancer cell phenotype by reprogramming cellular translation. Interleukin 24 (IL-24) is a 
tumor-suppressing protein, which can inhibit angiogenesis, sensitize cancer cells to 
chemotherapy, and induce cancer cell-specific apoptosis. As progresses via translation 
initiation mechanisms that are dependent either on the 5’cap structure (m7GpppN, where 
N can be any nucleotide) or an internal ribosome entry site (IRES) (Lomakin et al., 2000; 
Sonenberg et al., 1981). Also, Short 5’ untranslated region (5’UTR) mRNAs are enriched 
with TISU (translation initiator of short 5’UTR), a 12-nucleotide element directing 
efficient scanning-independent translation. The majority of translation initiation events in 
eukaryotes are mediated through cap-dependent translation whereby the 40S ribosomal 
subunit is recruited to the vicinity of the mRNA 5’ cap structure by the eukaryotic 
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initiation factor 4F (eIF4F) complex (Malka-Mahieu et al., 2017). eIF4F is comprised of 
eIF4A (an RNA helicase), eIF4E (the cap-binding subunit), and eIF4G (a large 
scaffolding protein for eIF4A, eIF4E, and other initiation factors). Once assembled at the 
5’ cap, the 40S ribosomal subunit in association with several initiation factors scans the 
5’UTR of the mRNA until it encounters a start codon in a favorable context, followed by 
polypeptide synthesis. eIF4A stimulates translation of both capped and uncapped mRNAs 
in vitro (Malka-Mahieu et al., 2017). 
Our previous studies have shown that a non-replicating adenoviral vector expressing 
Interleukin 24 (Ad.IL-24) induces apoptosis selectively in cancer cells, mediated through 
phosphorylation of eIF2-alpha (Persaud et al., 2017). The same non-replicating 
adenoviral vector expression IL-24 (INGN241) was used in patients with metastatic 
melanoma (Ramesh et al., 2010). Indeed, clinical trials in which Ad.IL-24 was 
administered by intra-tumoral injection in patients with advanced solid tumors, show 
promising results (Cunningham et al., 2005; Tong et al., 2005). We and others have 
extensively investigated and reported the underlying apoptotic mechanisms of IL-24 
protein treatment and Ad.IL-24 infection in preclinical studies in several cancer cells 
including prostate cancer cells (DU-145), melanoma (HO-1), breast cancer cells (MCF-7), 
and cervical cancer  HeLa cells (Menezes et al., 2018; Persaud et al., 2016). Our previous 
studies have shown that recombinant bioactive IL-24 protein as well as secreted IL-24 
protein (generated from Ad.IL-24-infected cells) exerts cancer-specific killing through a 
mechanism identical to Ad.IL-24 infection (Sauane et al., 2008). Interleukin 24 (IL-24) is 
a tumor suppressor protein that is currently in phase II clinical trials (Persaud et al., 2016). 
We have shown that IL-24 releases calcium (Ca2+) from ER-stores; induces ROS and 
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ceramide production; and induces inhibitory phosphorylation of eIF2-alpha (Persaud et 
al., 2017; Sauane et al., 2008, 2010). We also have demonstrated that S1R interacts with 
IL-24 and that IL-24:S1R complex is a critical upstream signal for IL-24-induced ER 
stress, calcium mobilization, and notably, phosphorylation of eIF2- alpha and apoptosis 
in cancer cells (Do et al., 2013). Consistent with our findings, Bina and colleagues have 
recently shown the interaction of IL-24 and S1R in an in silico analysis (Bina et al., 2017). 
Here we show that IL-24 causes inhibition of eIF4A in a wide variety of cancer cells.  
To address the physiological role of eIF4A in IL-24-induced apoptosis, we used 
overexpression of eIF4A. We demonstrate that IL-24 induces apoptosis through eIF4A 
inhibition, and mitochondria dysfunction. Importantly, the translation of mRNAs bearing 
long and structured 5’UTRs, such as the cell cycle regulators Cdc25C, c-myc, and 
ornithine decarboxylase (ODC), and the survival promoting proteins Bcl-2, Mcl1, Birca5, 
and X-linked inhibitor of apoptosis (XIAP), was reduced as a result of down-regulation 
of eIF4A triggered by IL-24. These results demonstrate that eIF4A plays a major role in 
IL24-mediated apoptosis in cancer cells. We show that eIF4A is required for IL-24-
induced apoptosis, whereby it acts by selective reduction of translation was observed for 
mRNAs harboring strong to moderate secondary structures in their 5’-untranslated 
regions (5’UTRs), including mRNAs encoding proliferation- and survival-promoting 
proteins.  
We also show that downregulation of eIF4A is required for IL-24-induced mitochondria 
dysfunction. Our data here provide strong evidence that S1R is a critical upstream signal 
for IL-24-induced eIF4A down-regulation, the translation of mRNAs bearing long and 
structured 5’UTRs, mitochondrial dysfunction and apoptosis in cancer cells. 
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3.2 Results 
3.2.1 IL-24-Dependent Inhibition of eIF4A Is Necessary to Mediate Apoptosis 
 
Two major events are rate-limiting in translation initiation: the formation of the ternary 
complex (eIF2, GTP, Met-tRNAi) binds the 40S ribosomal subunit, and the assembly of 
the eIF4F complex on the mRNA cap (Hinnebusch et al., 2014). We have previously 
demonstrated that IL-24 causes inhibition of translation, mediated through 
phosphorylation of eIF2-alpha (Persaud et al., 2017). Furthermore, phosphorylated eIF2-
alpha depletes the ternary complex necessary to initiate a new round of translation 
(Persaud et al., 2017). As we suggested, it is plausible that the effect of IL-24 on 
translation regulation is also related to a broader effect of IL-24 on translation regulation, 
possibly involving molecular players other than eIF2-alpha (Persaud et al., 2017). Now, 
we demonstrate for the first time that IL-24 inhibits eIF4A protein expression level in 
prostate cancer cells (DU-145), melanoma (HO-1), breast cancer cells (MCF-7), and 
cervical cancer cells (HeLa) (Figure 7A). This inhibition could be via multiple mediators 
such as PDCD4 and 15d-prostaglandin-J2. PDCD4 as tumor suppressor has been known 
to inhibit translation for more than a decade but it still remains unknown the exact 
mechanism by which it exerts this translation inhibition. One possible mechanism is that 
PDCD4 directly binds to and holds eIF4A to prevent it from form the eIF4F complex 
during translation initiation step as well as inhibiting eIF4A helicase activity involved in 
cap-dependent translation (Yang et al., 2003; Matsuhashi et al., 2019). Thus, IL-24 could 
stimulate PDCD4 production, which in turn inhibits and later decreases eIF4A level in 
cancer cells. Whereas for 15d-prostaglandin-J2, it has been shown to disrupt the 
interaction between eIF4A and eIF4G, preventing the eIF4F complex formation, which 
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limits mRNA translation and thereby limiting protein production and proliferation in 
cancer cells (Yun et al., 2018). Hence it is reasonable to hypothesize that IL-24 
overexpression can increase 15d-prostaglandin-J2 level in cancer cells to inhibit eIF4A 
level. IL-24 exposure also reduced viability of cancer cells (Figure 7B left panel) and 
apoptosis (Figure 7B right panel and Figure 1D). In addition, caspase-3 was detected in 
the same cancer cells to show IL-24 killing effect.  
Next, the requirement of eIF4A down-regulation for IL-24-induced apoptosis was 
analyzed by IL-24 treatment in cells overexpressing eIF4A. We investigated the 
inhibitory action of IL-24 on cell growth (Figure 7C left panel) and apoptosis (Figure 7C 
right panel and lower panel) on HeLa cells overexpressing eIF4A and control cells. Our 
data suggests that overexpression of eIF4A can restore cells from apoptosis and viability 
to control level, suggesting cell rescue from IL-24 treatment. This data is reinforcing the 
importance of eIF4A for cancer cells, but how eIF4A is involved in IL-24’s cancer cell 
killing effects will be further investigated and explained in later parts of this thesis. Taken 
together, these results show that down regulation of eIF4A is responsible for the 
inhibitory effect of IL-24 on cell growth and apoptosis. 
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Figure 7. IL-24-mediatd down-regulation of eIF4A is necessary to mediate apoptosis. (A) Melanoma (HO-
1), breast (MCF-7), prostate (DU-145) and cervical cancer cells (HeLa) were treated for 24 h with Ad.IL-
24 (100 pfu per cell) or Ad.vector (100 pfu per cell). Cell extracts were subjected to Western blot analysis 
to detect eIF4A, eIF4G, eIF4E and β-actin protein. (B) Cells were treated as described in (A), and cell 
viability was determined by trypan blue exclusion assay 4 days after treatment (left panel). Numbers 
represent the ratio of specific treatments to values in control cells (Ad.vector). Results of cell counting by 
trypan blue exclusion assay are plotted as mean ± SD of three independent experiments. *, p < 0.001 
comparted to Ad.vector. Cells were treated as described before, and then assayed for cell death using 
Annexin V staining a measure of apoptosis, and it was determined 48 h later by FACS analysis using the 
CellQuest software (Becton Dickinson). An average of three independent experiments is shown ± SD (right 
panel) *, p < 0.001 comparted to Ad.vector. (C) HeLa cells overexpressing eIF4A or control cells were 
treated with Ad.IL-24 (100 pfu per cell), and cell viability was determined by trypan blue exclusion assay. 
Numbers represent the ratio of specific treatments to values in control cells (Ad.vector). An average of 
three independent experiments is shown ± SD (left panel). *, p < 0.05 comparted to Ad.vector. Cells were 
treated as described in upper panel, and then assayed for cell death using Annexin V staining, and a 
measure of apoptosis was determined by FACS (right panel) *, p < 0.05 comparted to Ad.vector. Cells 
were treated as described in upper panel, cell extracts were subjected to Western blot analysis to detect 
cleaved caspase-3 and β-actin protein. (D) Melanoma (HO-1), breast (MCF-7), prostate (DU-145) and 
cervical cancer cells (HeLa) were treated for 24 h with Ad.IL-24 (100 pfu per cell) or Ad.vector (100 pfu 
per cell). Cell extracts were subjected to Western blot analysis to detect cleaved caspase-3 and β-actin 
protein. 
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3.2.2 IL-24 Appears to Affect Translation of mRNAs with Long, but Not Short, 
5’UTRs 
It has been established that eIF4A promotes the translation of mRNAs with long and 
structured 5’UTR features (Dai et al., 2017; Heerma-van-Voss et al., 2017). Translation 
initiation protein complexes mediate the recruitment of the 40S ribosomal subunit to the 
start codon in eukaryotic mRNA. Translation is primarily regulated at the initiation stage 
via the coordinated activity of translation initiation factors. Translation can be classified 
into cap-dependent or conventional and cap-independent or internal ribosome entry site 
(IRES) mediated based on specific structures in the mRNA itself (Lizuka et al., 1994; 
Pause et al., 1994; Van Der Kelen et al., 2009; Filbin et al., 2009; Akirtava et al., 2020; 
Rios-Fuller et al., 2020; Chen et al., 2020). Many translation initiation factors (eIFs) 
mediate the binding of mRNA to the ribosome, detecting the AUG start codon in the 5′
untranslated region (5′UTR) of the mRNA and binding of transfer RNAs, thus playing 
crucial roles in the translation machinery. Regulatory elements in the mRNA, especially 
sequence elements or secondary structures in 5’and 3’untranslated regions (UTRs), 
may block or recruit ribosomes and eukaryotic initiation factors (eIFs) to enable gene 
expression. The eukaryotic mRNA “cap” is a 7-methylguanosine on the first (5′end) 
nucleotide of the mRNA molecule and regulates cap-dependent translation. Some 
mRNAs with an extremely short 5’ UTR, known as translation initiator of short 5’UTR 
(TISU), may undergo cap-independent translation initiation through internal ribosome 
entry sites (IRESs). Those mRNA with IRES can be translated with or without the 
requirement of any canonical initiation factor (Pause et al., 1994; Filbin et al., 2009). 
Some mRNAs lack a 5’ UTR, the case of all mRNAs in mitochondria (Temperley et al., 
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2010). The protein complex eIF4F mediates cap-dependent translation. The eIF4F 
complex is comprised of eIF4A (an RNA-helicase that unwinds the 5’ UTR), eIF4E 
(binds the mRNA 5′ cap structure), and eIF4G (scaffolding protein for eIF4A, eIF4E, 
and other initiation factors). eIF4F facilitates the recruitment of ribosomes to the mRNA. 
Activity of the RNA-helicase eIF4F is required for unwinding the mRNAs 5′ UTR 
secondary structure, which allows eIF4F to scan the mRNA for the AUG codon, so that 
translation can start (Pestova et al., 2001; Prevot et al., 2003; Lee et al., 2012;). 
To confirm that IL-24 translationally down-regulates expression of long and structured 
5’UTR mRNAs, HeLa cells were co-transfected with Renilla (control) and Firefly FF) 
luciferase reporters harboring structured 5’UTRs or unstructured 5’UTRs. The FF 
reporters used were: IRF7 [5’UTR]-FF construct, which is long and translated in an 
eIF4E-dependent manner); ATP5O [5’UTR]-FF construct, containing a 4-nt portion of 
the TISU element (TISU: Translation Initiator of Short 5’ UTR. A sequence context 
flanking the translation start site regulating translation initiation for mRNAs with short 5’ 
UTR, usually ranging from 4 to 45 nucleotides) upstream of the initiation codon; ATP5O 
[TISU]-FF construct with a disrupted TISU element; ATP5O [5’UTR]-SL-FF construct, 
with a stable stem-loop structure (which is translated in an eIF4A-dependent manner); 
UQCC2 5’UTR construct without a TISU element; and NDUFS6 5’UTR construct with 
only a portion of the TISU element upstream of the initiation codon (Table 1). 
 
 
Table 1. List of primers used to generate luciferase reporter constructs. 





As shown in Figure 8, the main effect of treatment with IL-24 was seen on ATP5O 
[5’UTR]-SL-FF (Figure 8B) construct whose firefly luciferase activity was strongly 
repressed, suggesting inhibition of translation of this construct while other constructs 
showed smaller effects from IL-24 treatment. IL-24 had no effect on control Renilla 
luciferase. In addition to the previous results that IL-24 inhibits eIF4A, the following 
results of these assays suggest that IL-24 inhibits eIF4A expression (Figure 7A), which 
leads to inhibition of translation of mRNAs with long and structured 5’UTRs (Figure 8). 
As the other constructs do not possess structured or long 5’UTR, they do not require 
eIF4A to linearize and unwind, hence it is aligned with the fact that their expression 
levels are not significantly affected by IL-24 treatment. However, in order to further 
prove that the loop and complex structure in construct 2 is the reason why its expression 
is inhibited by IL-2 treatment, we would mutate the sequence in the loop to disrupt the 
structure, linearizing the gene construct 2, and then test its expression level under IL-24 
treatment. And if its expression level is still inhibited by IL-24 treatment, then the 
structure and loop is not the reason for its inhibition, whereas if its expression level is not 
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affected as much, then it would be reasonable to say that the complex structure and the 





Figure 8. IL-24 appears to reduce translation of mRNAs harboring structured 50UTRs. HeLa cells were 
transfected with firefly (FF) reporters harboring: (A) ATP5O 50UTR with a proximal portion of TISU 
element before the initiation codon (ATP5O [50UTR]-FF); (B) ATP5O 50UTR followed by a stem-loop 
structure (ATP5O (50UTR)-SL-FF); (C) IRF7 50UTR (IRF7 (5;UTR)-FF); (D) ATP5O 50UTR with a full 
TISU element (ATP5O (TISU)-FF); (E) NDUFS6 50UTR (NDUFS6 (50UTR)-FF); or (F) UQCC2 5 
0UTR (UQCC2 (50UTR)-FF). As a control, cells were cotransfected with a Renilla reporter. Cells were 
treated for 24 h with Ad.IL-24 (100 pfu per cell) or Ad.vector (100 pfu per cell). Each experiment was 
performed in independent triplicates, each consisting of three replicates, and data are shown as mean ± SD. 
p < 0.001 comparted to Ad.vector. RLU, relative light units. 
 
 
A B C 
D E F 
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3.2.3 IL-24 Appears to Reduce Translation of mRNAs Harboring Structured 
5’UTRs 
Expression of most proteins bearing long and structured 5’UTRs, such as the cell cycle 
regulators and the survival promoting proteins is translationally controlled and is highly 
dependent on the activity of the helicase eIF4A that function to unwind long and 
structured 5’ ends of mRNAs. To determine if IL-24 translationally down-regulates such 
mRNAs, we performed Western blot and quantitative real-time PCR analyses of lysates 
from HeLa cells treated with IL-24 or control (Ad.vector). Figure 9 shows that IL-24 
significantly reduced the expression of proteins that are involved in cell proliferation (e.g., 
Cdc25C, c-myc, and ornithine decarboxylase), and of survival promoting proteins (e.g., 
XIAP). This inhibition could be due to the structures and length in their respective 
mRNAs 5’UTR. Whereas the expression of housekeeping proteins such as Beta-actin, 
GAPDH, and Beta-tubulin was not affected as they do not have long and structured 
5’UTR (Figure 9A). This is also in accordance with the notion that translation initiation 
inhibitors preferentially inhibit oncogenic proteins production. Although the rapid 
turnover of ODC, the effect of IL-24 on ODC down-regulation is not absolute. It is 
plausible that this effect involves other molecular players such as antizyme-1, and 
localization of ODC in non-synchronized HeLa cells. In HeLa cells that overexpress 
eIF4A, IL 24 did not affect the levels of Cdc25C, c-myc, ornithine decarboxylase, and 
XIAP expression (Figure 9D), suggesting the protective effect of eIF4A on those mRNAs’ 
translation. Down-regulation of these proteins was likely at translation level because IL-
24 has minimal effects on the levels of the respective mRNAs (Figure 9B). These 
findings are consistent with the notion that inhibitors of eIF4A preferentially affect the 
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expression of proteins involved in cell proliferation and survival since they possess long 
and structured 5’UTR in their mRNAs, which require eIF4A to straighten and unwind for 
efficient translation to occur. This further proves the importance of eIF4A’ role in the 
previous inhibition of gene construct, which also requires this subunit to unwind and 
straighten the 5’UTR of the target mRNA. Also, this provides some insights about the 
reason why IL-24 only affects cancer cells and not normal cells. It could be that IL-24 
can inhibit eIF4A, which is more important for oncoproteins production and not house-
keeping proteins, so cancer cells, which are more dependent on oncoproteins than normal 




Figure 9. IL-24 treatment leads to reduction of mRNAs harboring structured 50UTRs. (A) HeLa cells were 
treated with Ad.IL-24 (100 pfu per cell) or Ad.vector (100 pfu per cell) for 72 h, and lysates were prepared 
and probed with antibodies specific to cdc25, c-myc, ODC, XIAP, GAPDH, α-tubulin, and β-actin. (B) 
HeLa cells were incubated with Ad.IL24 (100 pfu per cell) or Ad.vector (100 pfu per cell), and expression 
of cdc25, c-myc, ODC, XIAP, GAPDH, α-tubulin, and β-actin mRNA was determined by real-time PCR. 
 
 
3.2.4 IL-24 Treatment Leads to Mitochondrial Dysfunction 
- 44 - 
 
It has been established that inhibition of eIF4A triggers mitochondrial-mediated apoptosis 
by inhibiting translation of mRNAs with long 5’UTRs encoding proteins that maintain 
mitochondrial structural integrity (e.g., Bcl-2, Mcl1, and BIRC5) (Gandin et al., 2016; 
Matassa et al., 2013). Therefore, we investigated the effects of IL-24 on mitochondrial 
function. HeLa cells were treated with IL-24 for 72 h and mitochondrial membrane 
potential was measured using tetramethylrhodamine ethyl ester (TMRE), which can only 
accumulate in mitochondria when they are active. We found that IL-24 treatment induced 
depolarization of mitochondria (Figure 10A) as well as down-regulation of proteins 
implicated in the maintenance of the integrity of the mitochondrial outer membrane 
(Figure 10B left panel). These proteins share a critical characteristic of having complex 
5’UTR in their respective mRNAs, which would need eIF4A to process before translation 
can happen. Down-regulation of proteins implicated in the maintenance of the integrity of 
the mitochondrial outer membrane was likely translational because IL-24 has minimal 
effects on the levels of the respective mRNAs (Figure 10B right panel). In order to 
confirm that this inhibition on protein levels is due to limited mRNA translation and not 
by more degradation by lysosomes, future experiments will be included to block 
lysosomes and then test these proteins levels in IL-24 treatment and control. The 
requirement of eIF4A down-regulation for IL-24-induced mitochondria dysfunction was 
analyzed by IL-24 treatment together with overexpression of eIF4A. The action of IL-24 
on mitochondria dysfunction was tested in HeLa cells overexpressing eIF4A, which 
shows that overexpression of eIF4A can rescue the mitochondrial dysfunction as well as 
disrupted membrane potential (Figure 10C). These results together suggest that inhibition 
of eIF4A expression is responsible for the effect of IL-24 on mitochondria membrane 
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disruption and dysfunction. In addition, overexpression of eIF4A has shown an extended 
restore of expression of the gene construct with loop structure in 5’UTR, reinforcing the 
importance of eIF4A in the translation inhibition effects by IL-24 (Figure 10D). With the 
dysfunction and membrane disruption of mitochondria, cells will initially try to repair 
and safe them, but when the damage is beyond cell repair capability, autophagy will 
come in to recycle the impaired mitochondria in order to keep the cells functional and 
alive. Given that IL-24 is able to disrupt mitochondrial membrane and function when 
killing the cancer cells, it is possible that during this process, autophagy is also inhibited 
by IL-24 and damaged mitochondria will accumulate inside the cancer cells, leading to 
apoptosis eventually. To test this hypothesis, we would check autophagy markers 
including ATGs, Beclins and LCs by Western Blotting and immunostaining or by 
visualization with electron microscopy to see if there is any change of autophagosome 
structures inside cancer cells after IL-24 treatment or control treatment. To prove the 
hypothesis, we would observe there are decreased markers level in treatment compared 
with control cells. And in order not to miss the correct time point when this phenomenon 
happens, we need to perform a time-course experiment to catch that perfect timing. But if 
we don’t observe that decrease, it might be because autophagy is not involved in this 
process and we need to pursue another path by comparing cytochrome c levels after Il-24 
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Figure 10. IL-24 treatment leads to mitochondrial dysfunction. (A) HeLa cells were treated with Ad.IL-24 
(100 pfu per cell) or Ad.vector (100 pfu per cell) for 72 h. Mitochondrial membrane potential (MMP) was 
analyzed by monitoring TMRE fluorescence intensity. Results are presented as mean ± SD (n = 3) *, p < 
0.05 comparted to Ad.vector. (B) HeLa cells were treated with Ad.IL-24 (100 pfu per cell) or Ad.vector 
(100 pfu per cell) for 72 h, and lysates were prepared and probed with antibodies specific to Bcl2, Mcl1, 
BIRC5, and β-actin (Left panel). HeLa cells were incubated with Ad.IL24 (100 pfu per cell) or Ad.vector 
(100 pfu per cell), and expression of Bcl2, Mcl1, BIRC5, and β-actin mRNA was determined by real-time 
PCR (right panel). (C) HeLa cells overexpressed eIF4A or control cells were treated with Ad.IL-24 (100 
pfu per cell) or Ad.vector (100 pfu per cell) for 72 h. Mitochondrial membrane potential (MMP) was 
analyzed by monitoring TMRE fluorescence intensity. Results are presented as mean ± SD (n = 3) *, p < 
0.05 compared to Ad.vector. (D) HeLa cells overexpressing eIF4A cells were transfected with firefly (FF) 
reporters harboring ATP5O 50UTR followed by a stem-loop structure (ATP5O (50UTR)-SL-FF). As a 
control, cells were cotransfected with a Renilla reporter. Cells were treated for 24 h with Ad.IL-24 (100 pfu 
per cell) or Ad.vector (100 pfu per cell). Luminescence was monitored 48 h post-transfection. Data for 
Firefly luminescence normalized to Renilla luminescence. Each experiment was performed in independent 
triplicates, each consisting of three replicates, and data are shown as mean ± SD. *, p < 0.005 comparted to 
Ad.vector. RLU, relative light units. 
 
 
3.2.5 IL-24-Dependent Sigma 1 Receptor (S1R) Mediate eIF4A Down-Regulation, 
Translation of mRNAs Harboring Structured 5’UTRs and Mitochondrial 
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Dysfunction 
S1R is a protein chaperone, through whose regulation by specific ligands can have either 
cytoprotective or cytotoxic effects (Su et al., 2016). S1R agonists bind to S1R and 
promote cellular survival by preventing oxidative stress, while conversely, S1R 
antagonists, bind to S1R and inhibit tumor cell survival and induce apoptosis (Persaud et 
al., 2016). We have demonstrated that S1R is the common upstream initial signal 
transduction molecule involved in IL-24-induced cancer-specific apoptosis (Do et al., 
2013). We have determined that IL-24 action in cancer cells is mediated by an 
antagonistic effect of IL-24 on S1R. S1R antagonist-mediated cell death is inhibited by 
the prototypic S1R agonist SKF10047 or by overexpression of S1R (Persaud et al., 2016; 
Su et al., 2016). Therefore, we determined the possible role of S1R in the effect of IL-24 
on eIF4A down-regulation as well as mitochondria dysfunction. To that purpose, HeLa 
cells were transfected with S1R-expressing construct or treated with S1R agonist 
(SKF10047), and the action of IL-24 on eIF4A down-regulation as well as mitochondria 
dysfunction was tested. As shown in Figure 11, S1R agonist SKF10047 blocks Ad.IL-24-
mediated eIF4A down-regulation (Figure 11A, C), blocks mitochondrial dysfunction 
(Figure 11B) as well as translation of mRNAs with long 5’UTRs (Figure 11D). The 
requirement of S1R for IL-24-induced apoptosis was analyzed by IL-24 treatment along 
with S1R agonist SKF10047 or by overexpression of S1R and caspase-3 again was used 
to represent cell apoptosis under IL-24 treatment (Figure 11E). These results show that 
IL-24-mediated eIF4A down-regulation under the control of S1R as important mediators 
of apoptosis, translation of mRNAs with long 5’UTRs as well as mitochondrial 
dysfunction. The follow-up experiments will be conducted to investigate the mechanisms 
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by which S1R cam rescue the inhibition by IL-24 on cancer cells survival, mRNA 
translation as well we mitochondrial membrane dysfunction. One of the possible 
directions is to study the calcium transport between ER and mitochondria as it is an 
essential way by cells to cope with stress and also regulated by S1R. We would test by 
staining calcium content in ER and mitochondria and see if there is any shift of calcium 




Figure 11. IL-24-dependent Sigma 1 Receptor (Sig1R) mediate eIF4A down-regulation, translation of 
mRNAs harboring structured 50UTRs and mitochondrial dysfunction. (A) HeLa cells were transfected with 
firefly (FF) reporter harboring ATP5O 50UTR followed by a stem-loop structure (ATP5O [50UTR]-SL-
FF). Cells were cotransfected with a Renilla reporter. Cells were incubated with the Sig1R agonist 
(SKF10047) or overexpression of Sig1R with or without Ad.IL-24 (100 pfu per cell). Data for firefly 
luminescence normalized to Renilla luminescence. Each experiment was performed in independent 
triplicates, each consisting of three replicates, and data are shown as mean ± SD. *, p < 0.05. RLU, relative 
light units. (B) HeLa cells were treated as described in (A). Mitochondrial membrane potential (MMP) was 
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analyzed by monitoring TMRE fluorescence intensity. Results are presented as mean ± SD (n = 3). *, p < 
0.05. (C) HeLa cells were incubated with the indicated conditions. Cells were collected, protein purified, 
and subjected to western blot analysis to detect eIF4A, eIF4G and eIF4E protein. (D) HeLa cells were 
treated as described in (A), and lysates were prepared and probed with antibodies specific to cdc25, c-myc, 
ODC, XIAP, Bcl2, Mcl1, BIRC5, and β-actin. (E) HeLa cells were treated as described in A, and lysates 




Aberrant translation initiation has a profound impact on malignancy in the form of 
malignant transformation and maintenance (Hinnebusch et al., 2016; Bhat et al., 2015; 
Parra et al., 2017; Lindqvist et al., 2017; Mamane et al., 2006; Sonenberg et al., 1993). 
Hence translation initiation could provide an efficient mechanism to treat cancers. This 
work reports a previously unrecognized mode of inhibition of translation initiation 
whereby IL-24 inhibits eIF4A to induce apoptosis in cancer cells. Specifically, we 
demonstrate here that IL-24 treatment preferentially inhibits the translation of mRNAs 
possessing long and structured 5’UTRs at the initiation step, which could partially 
explain the cancer-specific killing effects by IL-24. In agreement with this model, our 
data demonstrate that IL-24 treatment inhibits eIF4A protein expression, and therefore 
inhibits the translation of mRNAs harboring structured 5’UTRs but not mRNAs with 
unstructured 5’UTRs. However, the exact mechanism by which IL-24 inhibits eIF4A 
remains unclear in this study, it would provide more insight in the future to uncover this 
pathway and the possible mediators could be PDCD4, 15d-prostaglandin-J2 and/or eIF4B. 
PDCD4, as tumor suppressor, has been known to inhibit translation for more than a 
decade but it still remains unknown the exact mechanism by which it exerts this 
translation inhibition. One possible mechanism is that PDCD4 directly binds to and holds 
eIF4A to prevent it from form the eIF4F complex during translation initiation step as well 
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as inhibiting eIF4A helicase activity involved in cap-dependent translation (Yang et al., 
2003; Matsuhashi et al., 2019). Thus, IL-24 might stimulate PDCD4 production or 
phosphorylation, which in turn inhibits eIF4A level, leading to decreased translation for 
oncogenes in cancer cells. Whereas for 15d-prostaglandin-J2, it has been shown to 
disrupt the interaction between eIF4A and eIF4G, preventing the eIF4F complex 
formation and limiting mRNA translation, and thereby limiting protein production and 
cell proliferation in cancers (Yun et al., 2018). Hence it is reasonable to hypothesize that 
IL-24 overexpression can increase 15d-prostaglandin-J2 level in cancer cells to inhibit 
eIF4A level. While another key translation initiation factor eIF4B has been found to 
enhance the affinity of eIF4A for mRNAs as well as stimulate eIF4A’s unwinding ability 
and efficiency up to 10-folds (Abramson et al., 1988; Ozes et al., 2011; Merrick et al., 
2015; Pelletier et al., 2019), I would hypothesize that IL-24 overexpression treatment can 
hamper eIF4B phosphorylation activity or its interaction with eIF4A in order to limit 
eIF4A’s mRNA unwinding ability, which then causes decreased oncoproteins production 
in cancer cells, leading to apoptosis. All these hypotheses are yet to be tested to deepen 
our understanding for IL-24 in cancer management. 
Moreover, we show that through the previously mentioned mechanism, IL-24 targets the 
expression of specific mRNAs harboring strong secondary structures in their 5’UTRs. 
These mRNAs encode proteins which function in survival (XIAP and Bcl-2) and in cell 
proliferation (Cdc25C, ODC, and c-myc). Importantly, we also show that overexpression 
of eIF4A confers cancer cells with resistance to IL-24-induced cell death and targets the 
expression of highly structured 5’UTRs mRNAs. Thus, we provide the first direct 
evidence for translational control for specific genes’ expression by IL-24 through the 
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regulation of eIF4A. This is consistent with the paradigm, in the field of translational 
regulation of gene expression, that down-regulation of eIF4A seems to be a promising 
cancer therapeutic approach with a pronounced effect on the translation of mRNAs 
encoding proteins important for proliferation, metabolism and survival, providing cancer 
cells a selective advantage (Heerma et al., 2017; Cencic et al., 2016; Chu et al., 2015; 
Parsyan et al., 2011; Steinberger et al., 2017).  This notion has been further supported by 
the research done by Dr. Chio and her team at Columbia University. In their recent study, 
a synthetic rocaglate CR-1-31-B has been shown to inhibit viability, survival, 
proliferation of pancreatic ductal adenocarcinoma cell lines, organoid growth and in-vivo 
tumor growth, resulting in longer tumor-bearing mice survival. According their data, this 
cancer cell inhibitory effect is likely through inhibition of eIF4A and does not cause 
significant toxicity at systemic level in mice. One of the mechanisms by which CR-31 
inhibits cancer cells and tumor growth is through eIF4A inhibition, which shifts and 
redirects translation in cancer cells to the one common in normal cells. Furthermore, Dr. 
Chio’s team has also established the importance of eIF4A in pancreatic ductal 
adenocarcinoma maintenance as well as the critical role of eIF4A-dependent translation 
in pancreatic ductal adenocarcinoma (Chan et al., 2019).  
In another study conducted in 2018, one of the classic eIF4A inhibitors silvestrol’s 
analogs EC143.29 and EC143.69 showed efficient blockade in protein synthesis 
regardless of 4E-BP1 expression status. Given that 4E-BP1 is a pivotal translation 
repressor that is commonly lost in pancreatic ductal adenocarcinoma to support and 
maintain malignancy, this 4E-BP1-independent inhibition on pancreatic ductal 
adenocarcinoma by silvestrol’s derivatives provides such a promising and favorable 
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potential therapeutic mechanism. Moreover, inhibition of 4E-BP1 by EC143.29 and 
EC143.69 also inhibits CDC6, which is a key regulator for DNA replication and repair, 
leading to limited cell proliferation and replication, possibly contributing to cancer cell 
and tumor growth inhibition by silvestrol both in vitro and in vivo. It is noteworthy that 
this set of in vivo experiments were conducted in C57BL/6J mice, which is the mice 
strain we use for our in vivo study with PD-L1, so this study also provides us specifically 
more confidence and guidance for our in vivo study (Müller et al., 2018).  
eIF4A1 is more abundant and better studied than eIF4A2. The two isoforms exhibit 
similar biochemical activities. However, their roles may not be equivalent. Notable 
differences include the following: eIF4A1 is predominantly synthesized during active cell 
growth, whereas eIF4A2 is produced during growth arrest; Suppression of eIF4A1 leads 
to increased eIF4A2 levels, but this change is insufficient to compensate for the ensuing 
cell death associated with eIF4A1 loss; eIF4A1 is essential for cell survival, but eIF4A2 
is not (Williams-Hill et al., 1997; Lu et al., 2014; Raza et al., 2015; Nebigil et al., 2020; 
Shen et al., 2020). While eIF4A1 seems to be more important for cell function than 
eIF4A2 and inhibition of eIF4A1 by IL-24 has such a potent impact on cancer cell 
proliferation and survival, it is worth investigating what happens to eIF4A2 when IL-24 
is downregulating eIF4A1 in cancer cells. Based on the present advancement in the field, 
I would hypothesize that upon IL-24 treatment, eIF4A2 is transcribed and translated into 
protein more than usual so that cancer cells can try to compensate for translation 
efficiency as both isoforms have been shown to participate in ribosome recruitment and 
translation (Robert et al., 2020), followed by cells transitioning from growing status to 
static status for a period of time before they eventually turn on apoptotic pathways and 
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die. In order to test this hypothesis, we would perform RT-PCR 12, 24 and 36 hours after 
IL-24 treatment to measure the mRNA levels of eIF4A2 as well as Western Blotting to 
determine protein levels of eIF4A2. Also, we would determine which cell cycle phases 
the cells are in at those time points too to match the eIF4A2 expression levels with cell 
growth status. 
Despite the progresses with the two major pathways IL-24 modulates, the way in which 
the two major regulatory branches, which regulate translation, ternary complex and eIF4F 
assembly, are coordinated remains largely unknown. Interestingly, Gandin et al. 
demonstrated a coordinated regulation of eIF2-alpha and eIF4E via CK2 and mTORC1 
(Gandin, et al., 2016). Our group recently demonstrated the role of IL-24 in inhibition of 
translation, mediated through phosphorylation of eIF2-alpha (Persaud et al., 2017). 
Consistent with this and with the new results reported here, both the ternary complex 
formation and eIF4F complex branches are inhibited by IL-24. It is yet not clear if both 
facets of translation initiation can be modulated, together or separately by one or more 
upstream signals triggered by IL-24.  
On the other hand, to characterize the signal transduction pathways responsible for the 
downregulation of eIF4A by IL-24, we focused on the upstream pathways involved in IL-
24 induced apoptosis. Our data here provide strong evidence that the IL-24 down-
regulation of eIF4A expression is Sigma 1 Receptor (S1R)-dependent (Figure 5). Also, in 
this study, we demonstrate that IL-24 induces eIF4A-dependent and S1R-dependent 
mitochondrial depolarization (Figure 11). Therefore, it is plausible that S1R coordinates 
TC and eIF4F complex assembly triggered by IL-24. Future research is required to 
delineate the mechanisms by which S1R down-regulates eIF4A expression triggered by 
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IL-24 and to investigate the mechanisms by which S1R mediated through both 
phosphorylation of eIF2-alpha and de-phosphorylation of 4E-BP1.  
In summary, IL-24 treatment has distinct advantage over the other general and 
conventional chemotherapies that usually target a wide range of cells in patients, which 
tend to cause significant side effects including bone marrow suppression and immune 
suppression, leading to infection. On the other hand, IL-24-mediated inhibition of 
translation initiation is not limited to any specific oncogene as many other approaches, 
but effective to an array of oncogenic proteins, which provides the potential to overcome 
the obstacle of resistance to treatment (Weinstein et al., 2002). IL-24-mediated inhibition 
of translation initiation could be harvested for either solo therapy or combination therapy 
with other therapies that also target translation initiation factors to amplify the inhibition 









































Immune system surveys tumors and eliminate many early tumors, but tumors evolve to 
evade immune system. Proteins produced by cancer cells that can suppress the immune 
system to inhibit anticancer immune responses and these proteins are called checkpoints. 
CTLA-4 (cytotoxic T lymphocyte-associated molecule 4) and PD-1 (programmed cell 
death protein 1) expressed on T lymphocyte function as immune system checkpoints that 
negatively regulate T lymphocyte activation. These inhibitory T lymphocyte receptors 
bind to effector molecules on tumor cells or antigen-presenting cells, thereby suppressing 
tumor-reactive T lymphocyte function. Therapies targeted against these negative 
immunologic regulators (checkpoints) are called immune checkpoint blockade therapies, 
which have been showing enlightening progress and are likely to be a major part of 
management for various cancer patients. The most promising ones include anti-PD-1 
(programmed cell death protein 1) and anti-CTLA-4 (cytotoxic T lymphocyte-associated 
molecule 4). 
PD-1 is a checkpoint of T lymphocyte when engaged with its ligands PD-L1. Upon 
binding between ligand PD-L1 and receptor PD-1, kinase-signaling pathways that 
normally cause activation of T-cells are inhibited, hence, leads to inhibition of 
proliferation and infiltration of T cells (Ishida et al., 1992; Freeman et al., 2000; Keir et 
al., 2006). The notion here is that if the interaction between PD-1 and PD-L1/2 or the 
expression level of PD-L1 is blocked, then T cells will not be inhibited and instead can 
remain activated and go fight cancer cells as usual. 
Increasing body of research exploiting ICBs has been underway for the past decade 
especially during the past few years after this method was awarded with Nobel prize. 
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Chen and his team studied the relationship between PA-L1 and PD-1 expression levels 
and oral squamous cell carcinoma and found that high expression of the pair is highly 
associated with suppressed immune response by T cells, faster tumor growth, resistance 
to treatment and poor prognosis (Chen et al., 2020). In addition to its solo treatment, anti-
PD-L1/PD-1 therapy has also been studied extensively in combination treatment for 
cancer patients as well. It was found that the efficacy and efficiency of anti-PD-L1 
treatment regimen is augmented when Mitomycin C is added to the regimen for small cell 
lung carcinoma (Luo et al., 2020). 
In the effort trying to determine the value of anti-PD-L1 treatment in vivo, scientists have 
widely used a strain of mice C57BL/6J. Turnis and colleagues have shown that inhibition 
of IL-35 can limit transplantable tumors’ growth of various types in C57BL/6J mice. 
Jonathan and his colleagues have proved that a combination between IL-12 and anti-PD-
L1 antibody has a better response in C57BJ/6L mice injected with MC38 cells than either 
treatment alone (Spencer et al., 2017; Jonathan et al., 2017; Turnis et al., 2016). We want 
to define if IL-24 can inhibit production of PD-L1 and if this inhibition can lead to T cells 
infiltration, activation, proliferation as well as suppressed tumor growth in vivo. Here we 
use C57BL/6J mice and MC38 mice colon cancer cells, which have been used by other 
groups for the purpose of testing immune checkpoint blockade therapies. Our preliminary 
data suggest that IL-24 can inhibit total PD-L1 expression level in vitro and colon tumor 
growth in vivo. Notably, this is a preliminary experiment with only two mice to test, 
optimize and find the best settings for our system, so there is no statistic study to be 
included here. But due to the promising and favorable results we discovered here, the 
next step would be to expand mice group to collect statistically significant results as well 
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4.2.1 IL-24 inhibits PD-L1 expression in vitro 
 
Our previous study suggested that IL-24 inhibits eIF4A expression levels in vitro (Zhong 
et al., 2018). In addition, Cerezo and colleagues demonstrated that inhibition of eIF4A 
contributes to PD-L1 downregulation in melanoma (Cerezo et al., 2018). Here we show 
for the first time that IL-2 inhibits total PD-L1 expression in vitro (Fig.12). Due to the 
fact that PD-L1 is known to only bind to PD-1 receptor when it is present on the cell 
surface and inactivate T cells (Iwai et al., 2002; Topalian et al., 2013), the next 
reasonable step in understanding the role of IL-24 in immune check point blockade 
would be to define if IL-24 specifically reduces the expression level of PD-L1 on the 
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Figure 12. IL-24 inhibits PD-L1 expression in vitro. DU145 cells were infected with Ad.IL-24 virus on 
Day1 (150pfu). Cells were treated with IFN-gamma (IFN-g) on Day2. Cells were collected, protein purified, 
and subjected to western blot analysis to detect PD-L1 and beta-actin (b actin). The experiment was 
replicated three times. 
 
 
4.2.2 Animal study experiment design 
 
Following the in vitro study, we proceeded to an animal study in order to further 
determine if IL-24 can inhibit PD-L1 and tumor growth in vivo. For this purpose, 
following the protocol established by Wei SC. and his colleagues (Wei et al., 2017), we 
did a preliminary experiment with two female C57BL/6J mice to test and optimize the 
settings in our system, including the number of cancer cells for injection, virus treatment 
dosage and length of the experiment. We injected mouse colorectal cancer MC38 cells 
into the right flank of the mice to form tumors, followed by treatment with either empty 
adenovirus or IL-24 adenovirus. We measured the tumor size every other day and then 




Figure 13. Mice experiment design. Two 8-week old C57BL/6J female mice were put in one cage and 
allowed to accommodate for 2 weeks prior to cancer cells injection. On day 0, 1x1010 MC38 cells were 
mixed with 100 µL PBS and injected subcutaneously into the right flank of each mouse. Mice tumors were 
observed and measured every other day. On day 18, tumors were palpable and sizable in both mice, then 
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185 µL of PBS with empty adenovirus was injected intratumorally in the control mouse and 185 µL of 
Ad.IL-24 solution was injected intratumorally in the treatment mouse. On day 22, the mice were sacrificed 
and tumors were harvested and measured for size and weight.  
 
 
4.2.3 IL-24 suppresses tumor growth in C57BL/6J mice 
 
After dissection of the tumors from the mice, we measured the weight and size of the two 
MC38 tumors. Our preliminary data shows that the treatment tumor is almost half of the 
control tumor in both weight and size (control tumor size 1.8 x1.25 x1.0mm, weight 1.1g, 
treatment tumor size 1.4 x1.35 x0.6mm, weight 0.5g), suggesting that IL-24 is able to 
suppress MC38 tumor growth in mice (Fig. 14). A possible mechanism by which IL-24 
suppresses tumor growth and size is by reinvigorating T cells to recognize cancer cells 
and respond to inhibit and kill cancer cells within the tumor. So next step we would 
detect whether T cells are being reactivated and responding to cancer cells with IL-24 
treatment. We would perform immunostaining with the tumor tissue and check levels for 
T cell markers to differentiate regulatory and cytotoxic T cells. To further test the 
mechanism of IL-24 on tumor growth inhibition, we would check for angiogenesis 
markers EGFR within the tumor as tumor needs extremely high level of energy and 
nutrient intake, IL-24 might being suppressing tumor growth by inhibiting angiogenesis 
to limit resources for tumor. 
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Figure 14. MC38 tumor growth is suppressed by Ad.IL-24. Mice tumors were observed and measured 
every other day. (a) MC38 tumor size is suppressed in the treatment tumor compared with the control 
tumor. (b) MC38 tumors were dissected and weighed on Day 22. Treatment tumor weight was suppressed 





Cancer cells are supposed to be targeted by immune system such as CD4 and CD8 T cells, 
but certain cancer cells develop mechanisms to evade immune system by suppressing T 
cells activation, proliferation or infiltration into the tumor (Wei et al., 2017). CTLA-4 and 
PD-L1 are two of the proteins used by cancer cells to inhibit immune system response 
and these proteins are termed as checkpoints, thus it is reasonable to target these 
checkpoints to prevent inhibitions of immune responses by malignant cells and this 
approach is named immune checkpoint blockade therapy. While immune checkpoint 
therapy has been shown to have significant and durable responses in clinic settings in 
patients with wide range of cancer types from lung cancer, kidney cancer and advanced 
melanoma, the side effects and adverse immune events are not negligible, since some 
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patients have developed serious response to the treatment such as dermatologic, 
gastrointestinal, hepatic and endocrinal damages (Postow et al., 2015). To alleviate these 
adverse events while not compromising the treatment efficacy, more research needs to be 
done to optimize the treatment in terms of dosage, scheduling and possible use of 
combination of drugs. 
For our group, the next step is to include more animals to collect statistically significant 
data. Furthermore, we plan to incorporate mass cytometry to analyze which T cells are 
activated and recruited into the tumor microenvironment as well as which cell markers on 
the cell plasma membrane are either up-regulated or down-regulated by IL-24 treatment 
in order to gain a better insight about how IL-24 is exerting its tumor suppression in vivo. 
With mice tumors, we will also check cell markers expression levels using 
immunohistochemistry to compare between control group and IL-24 treatment group. 
Our first targets include TBET, TIM3, ICOS and KLRG1. TBET is a marker for CD4 
effector cells proliferation, which are important effector cells fighting cancer cells in 
normal situation. TIM3 is a marker for CD8 activation. ICOS is a marker for CD4 T cell 
activation. KLRG1 is a marker for regulatory T cells, which are usually inhibited for the 
purpose to produce more effector cells from silent T cells (Wei et al., 2017). We 
hypothesize that IL-24 treatment will increase TBET, TIM3, ICOS while inhibiting 
KLRG1 expression to stimulate immune system to combat cancer cells as foreign bodies. 
In summation, immune check point blockade therapy, as a relatively new approach for 
cancer treatment, has been gaining increasing attention across the field due to its high 
efficacy, efficiency and specificity. While its detailed mechanisms are still yet to be 
defined by more research moving forward, we believe that our work will contribute to 
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deepen our understanding about and broaden the application of this concept either by 















































- 65 - 
 
5.1 IL-24 is an Inhibitor of Translation Initiation in Cancer Cells 
The significant roles of translation initiation factors in the development of various types 
of cancers have been established by other groups (Barna et al., 2008; Chu et al., 2016; 
Hinnebusch et al., 2016). Altered expression levels of translation initiation factors have 
been shown to contribute to initial cell malignant transformation and later cancer cell 
proliferation, invasion and metastasis (Weinstein et al., 2002; Barna et al., 2008; Miluzio 
et al., 2011; Hsieh et al., 2012). Manipulation on translation initiation could thus afford a 
strong mechanism employed for cancer therapeutic development. 
This dissertation presents strong results suggesting that inhibition of translation initiation 
with IL-24 could lead to cell apoptosis in cancer. Specifically, IL-24 inhibits eIF4A1 
expression level, which reduces the efficiency of translation of a group of oncogenes’ 
mRNAs due to their complex 5’ UTR structures. Notably, our group show in this work 
that decreased eIF4F complex by IL-24 can cause upregulation of pro-apoptotic proteins 
markers such as Caspase 3. Hence, we have the first direct evidence showing 
translational control of oncogenes by IL-24. This notion is in accordance with the new 
census that translational regulation of specific genes expression instead of only general 
rate of translation are causing cancer cells death as previously proposed (Bhat et al., 
2015). 
We also present that through this mechanism, IL-24 targets the expression of specific 
oncogenic proteins such as Bcl2, c-Myc, which are crucial for cancer cells to keep their 
malignant behavior. This approach clearly has a significant advantage over the traditional 
genotoxic chemotherapy that is toxic for all cells within the reach. On the other hand, 
with the selectivity of IL-24-mediated inhibition of translation for genes, it is not limited 
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to only one single oncogene as many current approaches are, but rather has an effect on 
many oncogenes, which has the potential to overcome the issue of resistance to treatment 
(Weinstein et al., 2002). While IL-24 has been studied extensively as a potential cancer 
therapeutic, but its inhibition on translation might also have a part in its other functions 
including antibacterial and antiviral effects, which still requires further investigation. 
In a nutshell, the discovery of translation initiation inhibition as one of the pivotal 
mechanisms of IL-24’s cancer-specific killing effect largely broadens our understanding 
about this molecule and its therapeutic potential in cancer treatment. 
 
 
5.2 IL-24 disrupts Mitochondrial Membrane Integrity Through Inhibition of eIF4A 
As previously proved by other groups, inhibition of eIF4A contributes to mitochondrial 
dysfunction and cell apoptosis (Gandin et al., 2016; Matassa et al., 2013). Here we 
hypothesized and proved that IL-24 is inhibiting eIF4A, which leads to mitochondrial 
dysfunction and cell apoptosis. 
In this project, we show that IL-24 is able to disrupt mitochondrial membrane potential 
and integrity by inhibiting translation of proteins important for maintaining the integrity 
of mitochondrial membrane such as cdc25C and XIAP, not only are these proteins 
important for maintaining mitochondria membrane, but they also have complex 5’ UTR  
structures in their respective mRNAs that rely on RNA helicase like eIF4A to unwind 
their structures to be translated. Conversely, overexpression of eIF4A is able to rescue 
this mitochondrial disruption by IL-24, further suggesting that eIF4A is the mediator in 
this IL-24 induced mitochondrial dysfunction. 
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5.3 Sigma 1 Receptor Can Rescue Cancer Cells From IL-24’s Killing Effect 
S1R, as a complex protein chaperone, can have either cytoprotective or cytotoxic effects 
depending the specific ligand and environment (Su et al., 2016). Here, we present data 
suggesting that S1R is a mediator in IL-24-induced cell apoptosis. Specifically, both S1R 
and its agonist can rescue mitochondrial dysfunction from IL-24 and save cells from 
being killed by IL-24, whose mechanism is still yet to be discovered from further study. 
Meanwhile, S1R is also able to directly prevent cell death caused by IL-24 inhibition on 
eIF4A. Taken together. our data is showing that S1R’s potential as a therapeutic target for 
anti-cancer drug development in future cancer treatment and management. 
 
 
5.4 IL-24 inhibits PD-L1 to inhibit cancer cells 
PD-L1, as one of the most studied immune checkpoints, has been shown in our system to 
be inhibited by IL-24 both in vitro and in vivo, leading to tumor growth inhibition and 
cancer cells apoptosis. This inhibition on tumor by IL-24 through PD-L1 may provide 
physicians one more option when treating cancer patients who are resistant to and/or 
prone to the toxicity of traditional chemotherapies. Compared to chemotherapies and 
other immunotherapies, immune checkpoint blockade method has been shown in the 
clinic to have better response in a group of cancer patients with non-small cell lung 
carcinoma, kidney cancer and advanced melanoma. 
Currently, the biggest hurdles with developing and applying ICBs treatment are that the 
treatment efficacy duration is short, recurrence rate is high, the price is not affordable and 
most importantly, the application is very much limited to a small subset of cancer patients. 
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In order to overcome these obstacles in order to better treat cancer patients, more research 
is warranted to uncover the mechanisms of how ICBs work and why we have the current 




Worldwide, cancer has been on the rise and is causing almost 10 million deaths every 
year. Effective and safe therapeutic targets and treatments are in high demand to alleviate 
cancer-related mortality and morbidity. 
IL-24 as a multidimensional pleiotropic cytokine has the potential to be exploited either 
as a therapeutic treatment in various diseases such cancer and some autoimmune diseases. 
IL-24 is such an fascinating member in IL-10 cytokine family, which has well-known 
anti-cancer effects in preclinical studies as well as Phase I/II clinical trials with patients 
with various kinds of advanced cancers. Within a few years of its anti-cancer effect 
discovery, IL-24 has had a fast progress into the clinic application where it has been 
found to be safe and effective when injected intratumorally using a non-replicative type 5 
adenovirus (Ad.mda-7; INGN 241) in a wide-spectrum of cancers that did not respond to 
other therapies, including melanomas and advanced carcinomas (Tong et al., 2005). 
Studies performed in the last two decades in many laboratories around the world are 
expanding our understanding of the molecular mechanisms of IL-24 functions. New IL-
24 targets are being identified in the area of apoptosis and toxic autophagy, which will 
facilitate development of preclinical therapeutic options that, combined with targeted 
therapies, may result in enhanced anti-cancer outcomes in patients. For future research, in 
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order to enhance our understanding and utility of IL-24 as a tumor suppressor with 
enormous potential in clinical applications, we would need to uncover how IL-24 
differentiates cancer cells from normal cells when exerting its pro-apoptotic and toxic 
autophagy functions, as this would give us new and deeper perspectives about therapeutic 
development. Also, genetically modifying IL-24 to boost its biological properties and 
therapeutic efficacy could afford a feasible tactic for pushing this cytokine into more 
clinical settings. 
While translation inhibitors have already entered clinical trials for many types of cancer, 
more insights into and understanding of how these inhibitors selectively suppress the 
expression of key molecules like C-MYC and PD-L1, could largely accelerate the rate of 
new drug discovery and clinical treatment response. 
In this dissertation, I present pathways involving IL-24 such as translation initiation and 
mitochondrial disruption, solidifying IL-24’s importance in cancer killing effects. 
Moving forward, understanding how IL-24 exploits these pathways when killing cancer 
cells in animal models and more human patients would provide the field more confidence 
and support when applying it clinically (Table 2). 
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Table 2: IL-24 as potential anti-cancer therapeutic in various cancers. IL-24 as a potential anti-cancer 
gene has been tested in various types of cancer in human patients including breast cancer, prostate cancer, 
pancreatic cancer and ovarian cancer, making it a very promising candidate as a cancer therapeutic. And in 
this work, we tested this anti-cancer effect in various cancer cell lines as well we trying to define the 
mechanisms by which IL-24 is able to kill cancer cells and leave normal cells intact. 
 
 
So far, most of the preclinical research efforts have been put into increasing the 
efficiency of delivery of IL-24 into cancer cells and boosting IL-24’s cancer-killing effect 
in combination with other small molecules and other cancer treatments. In addition, 
vaccinia viruses, which is widely used as vectors for infectious disease vaccines, have 
been tested to treat cancer both in vitro and in vivo (Deng et al., 2018; Zhang et al., 2015). 
In the future, development of more effective systemic delivery approaches for IL-24 gene 
could largely expand applications of this therapeutic cytokine since most of studies 
performed so far have used intra-tumoral injection of non-replicative adenoviruses 
expressing IL-24 genes. In the case of metastatic disease, which is the ultimate stage of 
cancer and most common cause of cancer patient death, an optimal delivery form of 
therapies is highly required. Systemic application of cytokine proteins may cause severe 
side effects like autoimmune response and nonspecific inflammation, which is one of the 
bottlenecks during therapeutic development using these molecules. Improved drug 
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delivery methods such as UTMD and nanoparticles, to apply IL-24-centered treatments, 
could provide clinicians a safer and more effective administration of this protein. Hence, 
it is highly significant and of huge clinical relevance to develop methods for IL-24-
centered systemic treatments and test them in preclinical animal models and then patients.  
More studies in different cancer types will further uncover more molecules contributing 
to IL-24’s mechanisms of killing effects, thus providing new perspectives about IL-24’s 
anti-cancer properties and helping further and expand use of IL-24 as a precise and safe 
therapeutic in cancer patients. 
As increasing amount of knowledge accumulates about pathways important for cancer 
development and maintenance over the past decades, these divergent pathways reflect the 
underlying cellular and molecular heterogeneity of the tumors, which eventually 
converge to the dependence on the activity of eIF4F complex, which contributes to the 
alterations to the oncogenes expression, driving malignant transformation, progression 
and even development of resistance to many therapeutics (Figure 15). 
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Figure 15: Oncogenic signaling pathways converge at cap-dependent translation initiation step at eIF4F 
complex. eIF4F complex has been shown to be at the convergent position of various pathways involved in 
cancer development, progression and drug resistance. eIF4A subunit inhibitors including Hippuristanol, 
Pateamine A and eFT226 have been shown to inhibit translation of oncogenes involved in cell proliferation, 
survival and metastasis. 
 
 
Thus, exploiting this complex—the critical point of convergence for various oncogenic 
stimuli—may present an effective means to overcome the heterogeneity that plagues 
current cancer management. Researchers have accumulated plenty of data about the 
mRNA cap structures and essential studies have defined their biologic function. It is these 
essential research studies that have led us to today’s deep knowledge about targeting the 
eIF4F complex, particularly for the treatment of cancer. Though, there is still a lot of 
work to do to translate from basic research to clinical application, there are plenty of 
opportunities to take advantage of and move forward our understanding about eIF4F 
complex to develop new therapies that inhibit the translation initiation of mRNAs 
encoding oncogenic proteins to better fight cancers. In summation, future studies to find 
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out more details about the mechanisms and connections between IL-24 and eIF4F are 





Figure 16. Potential pathways for T cell regulation. Various ligands, including CD40, CD70, MHCs and 
their respective receptors CD40L, CD27, LAG-3, TCR, KIR, are involved in T cell activation and 
inhibition regulation, providing more potential targets for ICBs therapeutics. The goal is to find out the 
relationship between these ligands and their receptors expresión levels and tumor growth in order to 
discover more mechanisms to inhibit tumor growth and metástasis.  
 
 
Meanwhile, immune system is tightly regulated in human to maintain a fine balance 
between overreaction to self, called autoimmune diseases, and under-reaction to foreign 
bodies such as tumor. In the view of their highly encouraging responses in cancer patients 
(Figure 17), ICBs have their own holdbacks such as autoimmune responses to digestive 
system, endocrine system due to dis-inhibition on PD-L1 and CTLA-4 pathways, which 
play key roles in preventing autoimmune diseases such as Grave’s disease, diabetes 
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Figure 17. The application of anti-PD-1/L1 in various types of cancer. Anti-PD-L1 therapeutics have been 
tested in various types of cancer including melanoma, small cell lung carcinoma, Hodgkin lymphoma and 
ovarian cancer patients with promising results showing cancer remission to different extents. Some patients 
stay in remission for months while others stay in remission for years. 
 
 
Though some physicians have used steroids to combat this fallback, but the effects of 
inhibiting immune cells activation could be counterbalancing the effects of using ICBs 
treatment to fight cancer. Furthermore, many questions, including which patients are 
more likely to have these adverse events, when to give patients treatment for these 
adverse events, can these patients be treated with ICBs ever again, have not yet been 
answered, so more communication between clinicians and researchers is needed to help 
the entire human species to better understand the mechanisms of these adverse effects 
and give the patients the best treatment to either prevent or alleviate them to get the best 
outcome for cancer patients (Ueda et al., 2003; Prokunina et al., 2002). 
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Due to its negative impacts on surviving cancer patients, clinicians need to be more 
cautious with ICBs treatments at the very beginning, including choosing the proper 
patients who are more likely to have more benefit from these ICBs than adverse events. 
To this point, there have been a few predictive markers for effective ICB treatment 
including PD-L1 expression level on tumor cell surface, microsatellite instability, 
mutation in cancer cells like EGFR, CD73, CD8+ T cell infiltration into tumor 
microenvironment, but due to their low reliability, low negative predictive values, vague 
cutting line, clinicians are still struggling with the application of this uprising novel 
treatment (Snyder et al., 2014; Larkin et al., 2015; Mahoney et al., 2015; Tokito et al., 
2016; Ishii et al., 2020). Thus, more clinical and basic research is warranted to further our 
knowledge to find more predictive biomarkers for more effective and less cumbersome 
immune checkpoint blockade therapy for patients suffering from cancers. This approach 
will also provide more cost-effective management with better patient response to 
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